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RESUMO 
O metabolismo das células cancerígenas é bastante alterado, já que estas células 
têm muito mais necessidades de energia, de poder redutivo e de intermediários que 
possam ser precursores biossintéticos. Consequentemente, a glucose, como principal 
fonte de energia de qualquer célula, tem o seu metabolismo alterado. O switch metabólico 
que leva a que quase todas as células cancerígenas metabolizem a glucose através da 
glicólise aeróbia em vez da fosforilação oxidativa chama-se Efeito de Warburg. Este efeito 
é causado pela desregulação da expressão de determinadas enzimas e proteínas e pela 
alteração de várias vias de sinalização. Apesar de este efeito ter sido descrito pela primeira 
vez nos anos 20 do século XX, as suas vantagens ainda não são completamente 
compreendidas. Este efeito está descrito no Carcinoma de Células Renais (CCR) que é o 
tumor sólido mais comum do rim adulto. O CCR corresponde a cerca de 80% dos tumores 
renais, sendo a neoplasia urológica mais mortal. A falta de um teste de rastreio standard e 
de biomarcadores que monitorizem o desenvolvimento da doença contribui para a elevada 
mortalidade observada. A carcinogénese do CCR está relacionada com a perda do pVHL 
e com a ativação do Fator de Indução da Hipóxia (HIF), que leva em última instância à 
ativação da transcrição de vários genes, incluindo o GLUT-1, um transportador de glucose. 
Uma das formas de regulação do GLUT-1 é através de microRNAs (miRNAs). MiRNAs são 
pequenos RNAs não-codificantes, responsáveis pela regulação da expressão génica a um 
nível pós-transcricional. Nos últimos anos os miRNAs têm sido alvo de estudo no campo 
da Oncologia devido à sua desregulação descrita em vários tumores, o que sugere a sua 
influência no desenvolvimento neoplásico.  
O objetivo do presente estudo foi estabelecer um perfil de expressão de miRNAs 
associado com o estado da glicólise no Carcinoma de Células Renais de células claras 
(CCRcc) que no futuro poderia ser usado como biomarcador de diagnóstico e/ou follow-up 
em doentes. Através de uma revisão sistemática da literatura, o GLUT-1 foi a molécula alvo 
selecionada assim como os miR-144 e miR-186. Para realizar o estudo, três linhas 
celulares foram usadas como modelo in vitro: uma linha celular renal epitelial proximal 
tubular normal (HKC-8) e duas linhas celulares de adenocarcinoma renal (786-O e FG-2) 
nas quais se procedeu à quantificação relativa dos miRNAs previamente mencionados nas 
células (níveis intracelulares) e nos respetivos meios (níveis extracelulares). A par da 
quantificação dos níveis de miRNAs foi feita a quantificação da expressão do RNA 
mensageiro (mRNA) do GLUT-1, do consumo de glucose, da produção de lactato e da 
capacidade metabólica. 
Neste estudo observou-se uma diminuição significativa dos níveis intracelulares do 
miR-144 na linha celular 786-O quando comparados com a linha HKC-8 (786-O vs HKC-8: 
Resumo 
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fold-decrease= 0,41, p= 0,028). Para além disso, este miRNA não foi detetado a nível 
extracelular na linha celular HKC-8, mas apresentava níveis de expressão circulantes 
maiores nas linhas 786-O e FG-2 (786-O: fold-increase= 64 472, p<0,001; FG-2: fold-
increase= 83 529 p<0,001). Também o miR-186 apresentou um decréscimo significativo 
nos níveis intracelulares das linhas celulares 786-O e FG-2 quando comparadas com as 
HKC-8 (786-O vs HKC-8: fold-decrease= 0,44, p= 0,010; FG-2 vs HKC-8: fold-
decrease=0,36, p= 0,005). Adicionalmente, este miRNA apresentava níveis de expressão 
extracelulares mais altos nas três linhas, mas a diferença é mais elevada nas linhas 
celulares tumorais (HKC-8: fold-increase= 26, p= 0,001; 786-O: fold-increase= 59, p<0,001; 
FG-2: fold-increase= 174 p<0,001). Esta desregulação dos miRNAs foi acompanhada de 
um aumento da expressão relativa do mRNA GLUT-1 (786-O vs HKC-8= 1360, p<0,001; 
FG-2 vs HKC-8= 1910, p<0,001), do consumo de glucose, da produção de lactato e da 
capacidade metabólica das células tumorais. Também se registou que os níveis de 
expressão de miR-186 intra e intercelulares diminuíram na linha celular HKC-8, após um 
estímulo com glucose, quando comparado com a condição controlo (fold-decrease= 0,09, 
p= 0,006 e fold-decrease= 0,21, p<0,001, respetivamente) Na linha celular 786-O, a 
expressão extracelular do miR-186 aumentou com o estímulo de glucose (fold-increase= 
4,2, p= 0,034) e na linha FG-2 a expressão extracelular de ambos os miRNAs também 
aumentou (miR-144: fold-increase= 31,8, p=0,030, miR-186: fold-increase= 7,11, p= 
0,044). Este estímulo levou ainda a um aumento da expressão relativa do GLUT-1 nas 
linhas HKC-8 e FG-2 (fold-increase= 282, p<0,001 e fold-increase= 1,9, p<0,001 
respetivamente), a uma diminuição do consumo de glucose, da produção de lactato nas 
linhas tumorais e da capacidade metabólica na linha 786-O. 
O miR-144 e o miR-186 têm como alvo o mRNA do GLUT-1. Assim a sua 
desregulação parece ser responsável pela sobrexpressão do GLUT-1 levando a um maior 
consumo de glucose. Este aumento do consumo é necessário para compensar a menor 
energia obtida através do desvio do metabolismo da glucose para a glicólise aeróbia, o que 
fica suportado pelo aumento da capacidade metabólica e da produção de lactato. 
Adicionalmente, um único estímulo de glucose no microambiente celular parece apresentar 
uma acentuada capacidade de modulação do microambiente, uma vez que foi suficiente 
para despoletar mecanismos epigenéticos com o objetivo de aumentar a disponibilidade 
do GLUT-1. 
A desregulação da excreção do miR-144 e do miR-186 define-os como bons 
candidatos a potenciais biomarcadores, não só para diagnóstico, mas também para 
prognóstico e follow-up. Os nossos resultados poderão ajudar a comunidade científica a 
dar um passo em frente no desenvolvimento de testes de rastreio eficientes, o que, em 
última instância, melhorará os cuidados de saúde e a qualidade de vida dos doentes. 
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ABSTRACT 
The metabolism of cancer cells is highly disrupted since these cells have a higher 
need of energy, reductive power and intermediates that can be precursors for biosynthesis. 
Consequently, glucose, being the major fuel of any cell, has its metabolism altered. The 
metabolic switch that makes almost every cancer cell metabolize glucose through aerobic 
glycolysis instead of oxidative phosphorylation is called Warburg Effect. This effect is driven 
by the deregulation of enzymes and proteins expression and disruption of signaling 
pathways. Although Warburg Effect was first described in the 1920s, its advantages are not 
fully understood. This switch is known to happen in renal cell carcinoma (RCC), which is 
the most common solid cancer of the adult kidney. RCC accounts for almost 80% of kidney 
cancers and is the most lethal one. The lack of a standard screening test and follow-up 
biomarkers contributes to this high mortality. RCC carcinogenesis is related to pVHL loss 
and Hypoxia Inducible Factor (HIF) activation, ultimately leading to the activation of several 
genes, including GLUT-1, a glucose transporter. One of the regulating mechanisms of 
GLUT-1 is through microRNAs (miRNAs). miRNAs are small non-coding RNAs that are 
responsible for the regulation of gene expression at a post-transcriptional level. They have 
been studied in the last few years in the Oncology field because of its deregulation in several 
cancers, that suggests they are implied in cancer development.  
The aim of this study was to establish a miRNA expression profile associated with 
the glycolysis status in clear cell Renal Cell Carcinoma (ccRCC) that, in the future, could be 
used as a biomarker of diagnosis and/or follow-up in patients. Through systematic literature 
review GLUT-1 was the selected molecule and so were miR-144 and miR-186. To perform 
this study, three cell lines were used, as in vitro model: one normal renal proximal epithelial 
tubular cell line(HKC-8) and two renal adenocarcinoma cell lines (786-O and FG-2), in which 
the expression of both miRNAs in the cells (intracellularly) and in the respective medium 
(extracellularly) was assessed. This was accompanied by the quantification of GLUT-1 
mRNA expression, glucose consumption and lactate production.  
We observed a significant decrease of miRNA-144 intracellular levels in 786-O when 
compared with HKC-8 (786-O vs HKC-8: fold-decrease= 0.41, p= 0.028). Moreover, this 
miRNA was not detected in HKC-8 extracellularly, but it presented higher circulating 
expression levels in 786-O and in FG-2 cell line (786-O: fold-increase= 64 472, p<0.001; 
FG-2: fold-increase= 83 529 p<0.001). Regarding miR-186, there was a significative 
decrease of miRNA intracellular levels in both 786-O and FG-2 when compared with HKC-
8 (786-O vs HKC-8: fold-decrease= 0.44, p= 0.010; FG-2 vs HKC-8: fold-decrease= 0.36, 
p= 0.005). Moreover, this miRNA presented higher extracellular expression levels in the 
three cell lines, but the difference is higher in the tumoral ones (HKC-8: fold-increase= 26, 
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p= 0.001; 786-O: fold-increase= 59, p<0.001; FG-2: fold-increase= 174 p<0.001). This 
deregulated expression was accompanied by an increase of GLUT-1 mRNA relative 
expression (786-O vs HKC-8 = 1360, p<0.001; FG-2 vs HKC-8 = 1910, p<0.001), glucose 
consumption, lactate and metabolic capacity in the tumoral cells. We also observed that, 
after a stimulus with glucose there was a decrease in miR-186 intracellular and extracellular 
expression in HKC-8 cells when compared with the control (fold-decrease= 0.09, p= 0.006 
and fold-decrease= 0.21, p<0.001, respectively). In 786-O cells, miR-186 extracellular 
expression increased with the glucose stimulus (fold-increase= 4.2, p= 0.034) and in FG-2 
both miR-144 and miR-186 extracellular expression also increased (fold-increase= 31.8, p= 
0.030, fold-increase= 7.11, p= 0.044, respectively). The glucose stimulus also led to aI an 
increase in GLUT-1 relative expression in HKC-8 and FG-2 cells (fold-increase= 282, 
p<0.001 and fold-increase= 1.9, p<0.001, respectively). This was accompanied by a 
decrease of glucose consumption and lactate production in both tumoral cells and also a 
decrease of metabolic capacity in 786-O cells. 
 Both miR-144 and miR-186 target GLUT-1. As so, their deregulation appears to be 
responsible for an upregulation of GLUT-1’s expression leading to a higher glucose 
consumption. This higher glucose consumption is needed to make up for the less energy 
obtained in the deviation of glucose metabolism into aerobic glycolysis, which is supported 
by an increased rate of metabolic capacity and by an increase of lactate production. 
Additionally, a single glucose stimulus from the microenvironment appears to have a high 
microenvironmental modulation capacity, since it was enough to trigger epigenetic 
mechanisms that would lead to a better availability of GLUT-1. 
The deregulation of both miR-144 and miR-186 excretion defines them as good 
candidates to potential biomarkers, not only for diagnosis, but also for prognosis and follow-
up. Our results can help the scientific community to move one step forward to the 
development of efficient screening and follow-up tests in RCC, which, ultimately, will 
improve the patients’ medical care and quality of life.  
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1. INTRODUCTION 
1.1 CANCER: GENERAL CONCEPTS 
In the last years the number of new cases of cancer has been continuously growing, 
becoming a public health problem and presenting itself as one of the main causes of death 
worldwide [1]. The GLOBOCAN 2012 (the online database of International Agency for 
Research on Cancer – IARC), estimated the occurrence of 14.1 million new cancer cases 
and 8.2 million cancer-related deaths in 2012 [2]. From these, approximately 3.45 million 
and 1.75 million, respectively, were attributed to Europe alone [3]. These are much greater 
numbers when compared with the ones registered worldwide in 2008 (12.7 million and 7.6 
million, respectively) [4]. The estimates are expected to increase and GLOBOCAN projects 
that, by 2025, there will be over 20 million new cases per year. Besides the growing aging 
of the world population, the increase of cancer cases may be due to lifestyle behaviors, 
known as cancer risk factors, such as smoking or certain eating and physic habits [2, 5]. 
Cancer incidence in Portugal has been rising along the years as well. In 2011, the 
Portuguese Northern Cancer Registry - RORENO (Registo Oncológico Regional do Norte) 
registered an increase of 9.8% in the number of cases with 18 491 new cancer diagnoses 
[6]. The increase is expected to continue and it is predicted that, by 2020, there will be 
21 444 new cases [7].    
Despite the great advances in the oncologic research in the last decades, the biology 
of cancer is still quite unknown, especially due to its heterogeneity, which reflects upon the 
failures in screening, diagnosis and treatment. 
Currently, cancer is described as a heterogeneous disease with several etiologies 
and, consequently, different evolutions and treatment approaches. It arises due to 
environmental and genetic interactions which can lead to the deregulation of several 
signaling pathways responsible for fundamental processes such as death, proliferation, 
differentiation and cell migration [8]. 
Carcinogenesis is a multifactorial and multiphasic process that ends with the 
development of a malignant neoplasia. It is normally described as a process of three 
phases: initiation, promotion and progression [9]. 
 Every day, cells composing the tissues of the human body experience different 
types of aggression. These aggressions may have origin in different types of carcinogenic 
factors (chemical, physic, viral and or biological) that will lead to different damages in cells, 
specifically in DNA (Deoxyribonucleic Acid). This is called initiation phase. Even though 
cells can repair these damages, some may lose this ability [10]. The following step, 
promotion, does not involve direct modifications in DNA structure. Alternatively, promotors 
increase the proliferation ability of initiated cells, contributing like this for the acquisition of 
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additional genomic and epigenomic lesions. Finally, tumor progression is characterized by 
the inactivation of several genes and the overexpression of others originating cells that 
proliferate uncontrollably and without suffering any control. This culminates in cells with 
malignant phenotypes that tend to become more and more aggressive with the increase of 
genetic and epigenetic alterations that end up occurring over time (Figure 1) [11] .  
 
 
 
Figure 1 – Schematic representation of carcinogenesis process (adapted from Abbas, K et al [9]). 
 
The genes more frequently involved in the beginning of cancer can be put into one 
of two classes: oncogenes or tumor suppressors genes. Proto-oncogenes codify molecules 
that regulate cell growth and differentiation. Gain-of-function alterations in proto-oncogenes 
convert them into oncogenes and lead to a constitutive expression of these molecules, 
promoting the cellular proliferation. On the other hand, tumor suppressor genes codify 
proteins that suppress cellular proliferation. Mutations in both alleles of these genes lead to 
loss of function of the proteins they codify for. Adding up to these two classes, genes 
involved in DNA reparation, cell cycle control and angiogenesis are also implied in the 
appearance of cancer [10]. 
Cancer cells, thereby, present phenotypes that discriminate them from normal cells. 
However, only in the year 2000, the Hallmarks of Cancer were proposed by Hanahan and 
Weinberg as an attempt to clarify the complexity of cancer [12]. To the initially six Hallmarks 
that characterized cancer cells, the same authors recently added four more to include the 
influence of tumor microenvironment to cancer development biology. Thus, tumors can now 
be described by their ability to sustain proliferative signaling, to evade growth suppressors, 
to enable replicative immortality, to activate invasion and metastasis, to induce 
angiogenesis and to resist cell death as well as by the capacity to avoid immune destruction, 
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to promote inflammation, by their genomic instability and mutations and by the deregulated 
cellular metabolism. This last Hallmark has been object of study for a long time and it has 
been object of increasing interest in the last decade (Figure 2) [13]. 
 
 
Figure 2  - The Hallmarks of Cancer as proposed in 2011 by Hanahan and Weinberg (adapted from Hanahan, 
D. and Weinberg, R. [13]). 
 
1.2 CANCER METABOLISM – THE GLUCOSE METABOLIC PATHWAYS 
Cancer cells have a higher rate of proliferation than normal cells. Because of that, 
they need a greater supply of energy, reductive power and intermediates as precursors for 
biosynthesis [14]. Cancer metabolism can be observed from two different perspectives: 1) 
If the supply of nutrients is optimal, the main purpose of tumor cells will be to obtain nutrients 
and to facilitate the assimilation of carbon into lipids, proteins and nucleic acids as to 
maximize cell growth and proliferation; 2) If there is lack of resources because of a harsh 
environment, cancer cells have to improve the consumption of nutrients modulating the 
microenvironment to obtain additional ones [15]. The glucose, amino acids and lipids 
metabolic pathways as well as autophagy, oxidative phosphorylation and formation of 
reactive oxygen species (ROS) are the processes where the main alterations in metabolism 
reprogramming of cancer cells occur [16, 17].  
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Glucose is one of the major “fuels” of any cell and its consumption is altered in 
cancer cells due to metabolism reprogramming [18]. Warburg Effect was one of the first 
mechanisms of metabolism reprogramming to be described [19]. Also called aerobic 
glycolysis, it is observed in almost every cancer cell and states the preference of cancer 
cells to use glycolysis instead of oxidative phosphorylation, even in the presence of oxygen 
[19]. In addition, there are several alterations in glucose metabolism to maximize either the 
production of energy or the production of new building blocks. These alterations happen in 
the pentose phosphate pathways, serine synthesis pathways and in the tricarboxylic acid 
cycle. Firstly, cancer cells consume much more glucose than normal ones, partly because 
of a higher expression of glucose transporters, like glucose transporter 1 (GLUT-1) [20]. 
Also, there is an overexpression of other enzymes in several types of cancer [18]. These 
enzymes include hexokinase (HK), aldolase (ALDOA), glyceraldehyde-3-phosphate 
dehydrogenase (GADPH), phosphoglycerate mutase 1 (PGAM1) and Lactate 
dehydrogenase (LDH) in glycolysis as well as glucose-6-phosphate dehydrogenase 
(G6PD) in pentose phosphate pathway or even serine synthesis pathway enzymes such as 
phosphoserine phosphatase (PSPH) [18]. This overexpression may be due to activation of 
oncogenes and suppression of tumor suppressors. On the one hand, c-Myc, Hypoxia 
Inducible Factor-α (HIF-α), K-RAS or Protein Kinase B (AKT) activate and promote the 
expression of these enzymes; on the other hand p53, genes from Sirtuin (SIRT) family and 
Phosphatase and tensin homolog (PTEN) are responsible for inhibiting some of these 
enzymes or the oncogenes that promote their expression [15]. 
Metabolism in cancer cells can be also dysregulated by mutations in genes related 
to metabolic pathways [14]. The most common mutated genes in cancer are FH, SDHA, 
SDHB, SDHC, SDHD, SDHAF2, IDH1 and IDH2 which encode for the subunits of four 
metabolic enzymes: fumarate hydratase (FH), succinate dehydrogenase (SDH) and 
isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) [14, 21]. Mutations in these eight genes 
have revealed to bring great advantages to cancer cells. The explanation to this advantage 
comes from the fact that their substrates inhibit α-Ketoglutarate-dependent dioxygenases 
[22]. These enzyme’s family catalyse the hydroxylation of diverse substrates, and they have 
been implied in pathways like collagen stabilization and endostatin production, fatty acid 
metabolism, hypoxic signalling, DNA and Ribonucleic Acid (RNA) repairing and epigenetic 
regulation, all of them of great importance to cells [14]. 
The dysregulation of metabolism in cancer cells can also be influenced by genetic 
polymorphisms in certain genes, particularly in the ones encoding for genes involved in 
glycolysis. Polymorphisms in glucokinase, HK-2, phosphofructokinase-muscle and GLUT-
1 genes were shown to influence prognosis of patients in several cancers [23-25]. 
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1.2.1  WARBURG EFFECT 
During the 1920s, Otto Warburg was one of the first to report an alteration in cancer 
metabolism: the aerobic glycolysis occurrence [19]. He and his colleagues were measuring 
O2 uptake and lactic acid production by cancer tissue, while calculating the amount of 
glucose consumed. Their data showed that cancer tissue consumed around ten times more 
glucose than normal tissue and produced more lactate as well. This was caused by an 
upregulated glycolysis. Also, even when there was a sufficient O2 supply, this kept 
happening. This singularity got known as Warburg Effect. Later, this process was 
demonstrated to be almost universal in several cancer types [26].  
When there is oxygen, differentiated cells transform glucose in pyruvate, through 
glycolysis. After that, pyruvate gets into mitochondria and enters into the tricarboxylic acid 
cycle, being transformed into carbon dioxide and nicotinamide adenine dinucleotide – 
hydrogen (NADH) is produced. NADH then fuels oxidative phosphorylation producing a 
great amount of adenosine triphosphate (ATP), with minimal production of lactate. It is only 
when oxygen is lacking that cells use exclusively glycolysis to transform glucose and large 
amounts of lactate are produced [27]. As it was already reported, this is not what happens 
with the majority of cancer cells, which seem to prefer to obtain energy through aerobic 
glycolysis. However, comparing both situations it is easily understood that aerobic glycolysis 
is a highly inefficient method of obtaining energy. In fact, while complete oxidation of glucose 
to carbon dioxide generates 36 molecules of ATP, glycolysis only generates 2, which means 
that it would be necessary a 19 times higher uptake of glucose to keep the same metabolic 
level [28].   
The Warburg Effect can be driven by the disruption of signaling pathways and by 
the deregulation of the expression of both metabolic enzymes and transport systems [29]. 
HIF signaling pathway, when activated, increases the transcription of glucose transporters 
genes and of most glycolytic enzymes, such as LDH and pyruvate dehydrogenase kinase 
(PDK) enzymes, restricting pyruvate entry into tricarboxylic acid cycle. Phosphoinositide 3-
Kinase (PI3K) pathway, in turn, integrates several molecules that are able to promote 
Warburg Effect, like AKT1 and mammalian target of rapamycin (mTOR) and is itself an 
activator of HIF transcription factors. Several glycolytic enzymes, like HK-2, pyruvate kinase 
2 (PKM2) and PDKs are upregulated, promoting aerobic glycolysis. Furthermore, data 
shows that the activity and abundance of metabolites can also contribute to this effect, since 
transporters like GLUT and sodium-glucose transport proteins (SGLT, an active transporter 
of glucose) are upregulated [30]. In addition, data suggests that downregulation of 
mitochondrial pyruvate transporter 1 and 2 (MPC1 and MPC2), which are responsible for 
transporting pyruvate into the mitochondria, may help maintain the Warburg phenotype [29].    
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After more than 90 years the question that remains unanswered is: why do cancer 
cells undergo aerobic glycolysis, despite its apparent inefficiency? The first attempt to 
answer this question came from Warburg himself. He proposed that a dysfunction in 
mitochondria was the cause of this effect. This hypothesis was proven to be incorrect since 
roughly 66% of cells that kept oxidative phosphorylation capacity would metabolize through 
fermentation [26]. Later, in the 1970s, Efraim Racker proposed that the Warburg Effect 
originated from imbalances in intracellular pH due to defects in ATPase activity [31]. Despite 
several proposed causes of the Warburg Effect, they remain controversial and several 
hypotheses are still being discussed. Some believe that Warburg Effect comes as an 
advantage because it is a faster way for cancer cells to obtain ATP [32]. Others affirm that 
this effect supports better the high biosynthetic needs of these type of cells [33]. More 
recently, some scientists presented a theory saying this switch brings an acidification of the 
microenvironment, which is a great advantage to cancer cells, and others defend that this 
effect has direct signaling functions [34]. Even the theory that points Warburg Effect as the 
cause of carcinogenesis is still discussed nowadays [28]. Therefore, there is a continuous 
need of more studies and new experiments in order to support or revoke the theories 
described above.  
 
1.3 RENAL CELL CARCINOMA  
Kidney cancer represents 5% and 3% of all adult cancers in men and women 
respectively, being the 7th and 10th most common cancer for each gender [1]. From all the 
adult solid kidney cancers, Renal Cell Carcinoma (RCC) is the most common, accounting 
for 80% of all cases and it represents the most lethal urological cancer [35]. In Europe alone, 
84 400 new cases were stated in the year of 2012 [3]. Kidney cancer has been rising in the 
north of Portugal as well and in 2010 it became part of the ten most frequent cancers, 
occupying the ninth position [6]. RORENO estimates there will be 451 new cases of kidney 
cancer by 2020 opposing to the 286 cases stated in 2008 [7].  
There appears to be a geographic disparity of incidence and mortality rates of RCC, 
since the incidence rates in Northern America, Western Europe and Australia are higher 
when compared with the ones observed in India, China and Africa (Figure 3). Concerning 
mortality rates, they are higher in the european continent, mainly in Central and Eastern 
Europe. This variation may be explained by differences in diagnosis, treatment, genetic 
patterns, environmental factors and lifestyle habits [36]. 
Introduction 
 
GLUT-1-related microRNAs and the Glycolysis in Clear Cell Renal Cell Carcinoma 
32 
 
Figure 3 – Global kidney cancer incidence (annual cases per 100 000 people): this incidence is higher in 
developed countries (adapted from Hsieh, J. et al [36]). 
 
It is not yet clear what causes kidney cancer but epidemiological studies point out 
several factors that seem to be involved in the etiology and development of these tumors.  
There is a 2:1 predominance of diagnosis in men over women, with a peak of incidence 
between the age of 60 and 70 years old [36]. Besides that, certain lifestyle habits such as 
smoking habits as well as excessive body weight and the exposure to certain chemical 
substances like cadmium, some herbicides and organic solvents are also pointed out as 
potential risk factors [37].  
As a consequence of their location, these tumors are many times found due to 
imaging tests (computed tomography and magnetic resonance) performed with other 
clinical purposes, such as routine exams. Additionally, the anatomic location of the kidney 
is also responsible for the fact that renal masses remain asymptomatic and non-palpable 
through most of their development, meaning that, when the patient starts to present 
symptoms, the tumor is in a more developed stage [35]. In fact, when tumors become 
symptomatic with the classical triad – flank pain, gross haematuria and palpable abdominal 
mass – they already have bigger diameters and prognosis are worse [38]. 
The anatomic characteristics of these tumors and the lack of a standard screening 
test are responsible for the fact that one third of patients are still diagnosed with local 
invasive or metastatic disease [39]. The 5-year survival rate for patients with organ confined 
disease ranges from 88% to 95% whereas patients with invasive disease only show a 59% 
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of 5-year survival rate and this rate decreases even more in distant metastatic disease 
(20%) [36]. 
RCC is staged according to the AJCC (TNM) staging system that takes into account 
tumor size(T), the extent of spread to nearby regional lymph nodes (N) and whether the 
cancer has metastasized (M) [40]. Fuhrman grading system is also widely used and grades 
the tumor accordingly to the cell nucleus. It defines four nuclear grades (1-4) gradually 
increasing the nuclear size, irregularity and nucleolar prominence. Prognosis evaluation 
normally considers anatomic, histologic, clinical and molecular factors. The International 
Society of Urological Pathology (ISUP) validated six prognostic factors in 2016 to be 
reported in routine practice: the histological subtype, the nucleolar grading system, 
presence of sarcomatoid and/or rhabdoid features, necrosis, microvascular invasion and 
pTNM staging [35].  
Treatment options for RCC depend mainly on the stage of the tumor. Surgery is the 
primary treatment for surgically resectable RCC and it normally has a curative intent. 
However, in patients with inoperable or metastatic tumors it can only be used for palliative 
reasons [35]. As so, these patients undergo systemic treatment with targeted agents and/or 
immune check-point inhibitors [41]. Targeted therapies include tyrosine kinase inhibitors 
(TKIs), vascular endothelial growth factor (VEGF) antibodies and mTOR inhibitors. 
Immunotherapy has also been used since the 1990s with interferon-α and interleukin 2 (IL-
2), with limited efficacy. Nowadays therapies with antibodies against programmed cell death 
protein 1 (PD1) and programmed cell death protein 1 ligand 1 (PDL1) or inhibitors of T cell 
checkpoint cytotoxic T lymphocyte-associated protein 4 (CTLA4) are being explored in 
concomitance with each other or with targeted therapies since their solo effect has been 
shown limited. In general, these therapies ameliorate the outcome of patients [36]. 
However, these tumors rapidly develop resistance through escaping mechanisms that 
involve alternative pathways activation in order to sustain their development [42].  
 
1.3.1 RENAL CELL CARCINOMA MOLECULAR BIOLOGY 
RCC comprises a heterogeneous group of cancers derived from renal tubular 
epithelial cells. The classification of this group of cancers has been revised due to 
histopathological and molecular advances. According to the WHO 2016 classification, there 
are 16 subtypes of RCC but the major subtypes, with more than 5% incidence, are clear 
cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC) [36, 43]. ccRCC 
is the most common one accounting for 75% of all cases and the majority of deaths and it 
is characterized by a high tumor cell lipid content and a richly vascularized tumor stroma[36]. 
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However, even within this subtype there is great intra and inter-tumor heterogeneity which 
explains the different clinical outcomes observed [36].  
The molecular mechanisms behind ccRCC development and progression are still 
not completely understood. However, the pVHL/HIF pathway is one of the established 
signaling pathways as altered in these tumors [44, 45]. Von Hippel Lindau protein (pVHL) 
is a tumor suppressor protein involved in several functions related with the embryonic 
development and with the regulation of microtubule stability and cilia development. 
Nevertheless, its dominant function is to target HIF-α for proteolysis [46].  
Under normoxic conditions, pVHL, the substrate recognition component of an E3 
ubiquitin ligase, targets the hydroxylated HIF-α subunits (HIF-1α and HIF-2α) for 
ubiquitination and proteasomal degradation [46]. Both HIF-1α and HIF-2α have two 
transcriptional activation domains: the N-terminal transactivation domain (NTAD) and the 
C-terminal transactivation domain (CTAD), enabling transcription once restrained to DNA 
[47]. When oxygen is present, these domains are hydroxylated by prolyl hydroxylases 
(PHDs) and factor-inhibiting HIF (FIH) at the NTAD and the CTAD, respectively. pVHL then 
binds to the hydroxylated HIF-α and to elongin C. Subsequently, this elongin recruits three 
components of an E3 ubiquitin ligase (elongin-B, cullin-2 and ring-box 1 – RBX1). This 
ligase targets HIF-α for ubiquitination and degradation by 26S proteasome [48].  
During hypoxia, HIF-α cannot be hydroxylated and as so, HIF-α does not bind to 
pVHL, ending up being accumulated in the cell cytoplasm. Due to that, HIF-α translocates 
to the nucleus where it heterodimerizes with HIF-β. The newly formed complex binds to 
hypoxia response elements (HREs) on nuclear DNA, recruits co-activators p300/CBP to the 
CTAD of HIF-α, which leads to the transcription of target genes [49, 50]. This activation 
includes  genes  involved in several processes like the development of blood vessels 
(Vascular endothelial Growth Factor – VEGF; Vascular endothelial Growth Factor Receptor 
– VEGFR), cell proliferation (Transforming Growth Factor alpha – TGF-α), glucose 
metabolism (GLUT-1 and GLUT4), pH regulation (Carbonic Anhydrase IX - CAIX) and cell 
migration (C-X-C motif chemokine receptor 4 - CXCR4) (Figure 4) [44, 51]. 
Loss of pVHL leads to a state of constant pseudo hypoxia, where HIF-α accumulates 
in the nucleus even if oxygen is present. This loss can be due to germline mutations in the 
VHL gene which is located at chromosome 3p25 [52]. Patients with this type of mutations 
have a rare autosomal dominant hereditary familial tumor syndrome which brings a higher 
risk for developing highly vascularized tumors in multiple organs. ccRCC is one of these 
tumors and it is the most aggressive one. Loss-of-function coding mutation in VHL, 
chromosomal aberrations on chromosome 3p25 affecting the VHL locus as well as 
hypermethylation of the VHL promoter explains 60 to 80% of sporadic ccRCC cases in 
Introduction 
 
GLUT-1-related microRNAs and the Glycolysis in Clear Cell Renal Cell Carcinoma 
35 
which the genetic mechanism of tumor initiation mimics the one seen in VHL disease [51, 
52].  
The other histological subtypes of RCC normally do not present VHL alterations but 
histologically mixed variants of these tumors may have components of clear cell with these 
mutations [52]. 
Typically, ccRCC presents resistance to chemotherapy and radiotherapy, making 
target therapies the best option for metastatic tumors treatment. However, drugs that 
modulate the pVHL/HIF/VEGF are expensive, have major side effects and an objective 
response rate was only observed in 45% of patients. This may be due to the fact that these 
treatments don’t target directly the tumor cell, allowing the potential for disease progression 
despite treatment [50].  In fact, about 25% of patients do not seem to experience any clinical 
benefit from these therapies, while in most of cases, patients develop resistance after a 
median of 5-11 months of treatment [53, 54]. These therapy failures show the necessity of 
more investigation into the molecular biology of ccRCC to develop new effective targets, 
therapies or treatment schemes. 
ccRCC clinical practice also presents a lack of accurate biomarkers of diagnosis, 
prognosis and therapy response monitorization. A biomarker is a biological feature that is 
objectively measured and evaluated as an indicator of normal biological or pathological 
processes, or a response to a therapeutic intervention [55]. An ideal biomarker must be 
easy to measure through minimal invasive methods, easy and not expensive to quantify, 
specific and sensitive to the disease of interest, able to detect the disease before symptoms 
and useful in the response to therapy’s monitorization [56]. The main struggles with the 
search for an ideal biomarker is the susceptibility to degradation in body fluids that mitigates 
their signal and the possible endogenous production by normal cells that may increase it 
[57]. From all the possible biomarkers studied in RCC, recent data proposes that the 
microRNAs (miRNAs) seem to be able to monitor diagnosis, prognosis and therapy 
response [45, 58-60]. However, they still need further validation in different types of body 
fluids and tissues [58, 61].  
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Figure 4 – Molecular basis of ccRCC development: in the presence of oxygen, HIF-α is targeted for degradation; 
when oxygen is lacking or when there is loss or inactivation of pVHL (ccRCC case) HIF-α accumulates in nucleus 
and induces transcription of several target genes (adapted from Dias F [45]). 
 
1.4 MicroRNAs 
MiRNAs are a class of short RNAs of 19 to 25 nucleotides that negatively regulate 
gene expression at a post-transcriptional level through the binding to complementary 
sequences in the 3’ untranslated region (3’UTR) of messenger ribonucleic acids (mRNAs). 
In just a few years since their discovery, miRNAs have been gaining importance as more 
and more is understood about their impact in many molecular components in both normal 
and pathological cells [62].  
MiRNAs biogenesis is a multistep, well described and generally conserved process 
[63].  MiRNAs are originated from intergenic or intronic regions of either coding and non-
coding genes. In the nucleus, they are majorly transcribed by RNA polymerase II (Pol II) as 
part of long primary RNA (pri-miRNAs). These pri-mirs have well defined hairpin structures, 
which are then cleaved by Microprocessor: a multiprotein complex composed by a cofactor, 
double stranded RNA binding protein DiGeorge syndrome critical region 8 (DGCRG8), that 
recognizes the stem-loop structure of the pri-miRNA and interacts with it, recruiting the 
double stranded RNAse III enzyme (DROSHA) which then cleaves it producing a secondary 
precursor of about 70 nucleotides, called pre-miRNA. Pre-miRNA is, then, exported to the 
cytoplasm by Exportin-5, a nuclear transporter that recognizes its stem-loop structure. 
There, pre-miRNAs are further processed by an RNase III enzyme, DICER1, being 
transformed in double-strand miRNAs which are unwound by a helicase, finally reaching 
their final form of mature miRNAs. They then associate with Argonaute 2 (AGO2) in the 
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RNA-induced silencing complex (RISC) in order to bind to the complementary 3’-UTR of 
their specific target mRNAs (Figure 5) [64]. 
 
 
Figure 5 – MiRNA biogenesis and function (adapted from Dias F [45]). 
 
MiRNAs known function is, thus, to regulate mRNA expression. It is still not 
understood how the binding of the RISC complex to 3’-UTR of the target mRNA leads to its 
blockage. Some believe the deadenylation of the polyadenylated 3’-end may lead to mRNA 
degradation, or that there is a competition between AGO-miRNA complex and translation 
initiation factors that reduces translation initiation. Others state there may be an induction 
of premature termination and impaired elongation when the complex AGO-miRNA binds 
with 3’-UTR of mRNA or even that this complex can have the ability of recruiting peptidases 
that will degrade the growing polypeptide during translation [65]. Some miRNAs may bind 
to the open reading frame or promoter region of target mRNAs leading to gene suppression. 
Besides, there are certain miRNAs that bind to the 5’-UTR of mRNAs and upregulate the 
target gene expression [66].  
MiRNAs are characterized for their dynamic expression: each miRNA regulates up 
to 100 different mRNAs and more than 10 000 mRNAs seem to be directly regulated by 
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miRNAs. As so, the same gene can be targeted by several miRNAs and a single miRNA 
can target multiple genes. This dynamic expression means that the aberrant expression of 
miRNAs may affect multiple transcripts and influence many biological processes including 
cell development, differentiation, apoptosis and proliferation, crucial processes during 
cancer development [57]. While many miRNAs act as oncogenes, since they downregulate 
tumor suppressor genes and are reported as overexpressed in tumor multiple miRNA-
profiling studies; others act as tumor suppressors, downregulating oncogenes and being 
mostly underexpressed in cancer [67] Despite their clear importance in cancer biology, the 
multitude of targets and tissue specificity makes it difficult to understand the precise role 
they play in the disease process and the genes affected by their deregulation[59].  
One of the most important features of miRNAs is that they have different expression 
patterns in normal cells when compared with cancer cells, and even between cancer 
subtypes, which makes them excellent candidates for biomarkers. Besides, expression 
levels of miRNAs are reproducible and conservative among individuals from the same 
species [45]. Apart from that, circulating miRNAs remain stable in extreme conditions 
(boiling, very low or high pH, extended storage and freeze-thaw cycles). Finally, they appear 
to be protected from RNase activity. All these characteristics make them excellent 
biomarkers candidates [68]. 
The impact of miRNAs in RCC’s biology has been raising interest among 
researchers, especially due to their applicability as biomarkers. Several ccRCC oncogenes 
and tumor suppressors genes (Epidermal Growth Factor Receptor – EGFR, mTOR, VHL, 
HIF-1 α, Platelet-derived growth factor subunit B 1 – PDGFβ) have been indicated as 
potential targets of certain miRNAs and several miRNAs have already been detected in 
patients’ biofluids and associated with disease prognosis [69-71]. Moreover, Youssef and 
coworkers even proposed a classification system that is able to distinguish between the 
different RCC subtypes using unique miRNAs signatures in a maximum of four steps. The 
system has a sensitivity of 97% in distinguishing normal RCC, 100% for clear cell RCC 
subtype, 97% for papillary RCC subtype and 100% accuracy in distinguishing oncocytoma 
from chromophobe RCC subtype [72]. 
 
1.5 GLYCOLYSIS IN RENAL CELL CARCINOMA and miRNAs 
The Warburg Effect is well documented in RCC. This effect can be driven by an 
interruption of the Krebs Cycle, germline inactivating mutations in genes that encode 
enzymes like FH or SDH, upregulation of HIF, increased levels of reactive oxygen species 
or activation of different pathways like NRF2/KEAP1 and PI3K/AKT/mTOR. In ccRCC (both 
sporadic and hereditary), the most likely cause of the Warburg Effect is the upregulation of 
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the HIF pathway. In most cases, HIF- α degradation stops occurring due to VHL alteration. 
However, HIF-α can also be stabilized by other mechanisms like RAS activation or 
accumulation of Krebs cycle substrates[73].  
In 2013, The Cancer Genome Atlas (TCGA) performed a comprehensive molecular 
characterization of ccRCC, using more than 400 ccRCC samples and concluded that 
patients that have tumors with higher stages and higher Fuhrman grades are associated 
with a metabolic shift consistent with a suppression of oxidative phosphorylation and a 
subsequent dependence upon glycolysis for energy [74]. The finding of the Warburg shift in 
ccRCC, opened the door for the development of new targeted therapies.  In a recent review, 
Schodel and co-workers, summarized the HIF target genes related to glycolysis in ccRCC, 
which could be possible therapeutic targets in targeted therapy involving the glycolysis 
pathway. The most relevant genes are the GLUT-1, LDHA, ALDOA, HK2, 
Phosphofructokinase (PFK) and Phosphoglycerate 1 (PGK1). [51]. Additionally, SGLT2 can 
also be considered important for glucose metabolism in ccRCC, since it is expressed in the 
kidney tissue and is responsible for glucose reabsorption after glomerular filtration and may 
play a role in glucose metabolism [75]. It is important to note that all these enzymes and 
transporters have been reported as up-regulated in RCC [74, 76-81]. 
Among them, GLUT-1, a glucose transporter with a basal glucose uptake function 
that is ubiquitously expressed, plays a crucial role. In order to engage the Warburg Effect, 
cancer cells use much more glucose than a normal cell, which means that their ability to 
bring glucose into their cytoplasm needs to be increased. Therefore, miRNAs associated 
with GLUT-1 may be useful biosensors of the increase or decrease of this transporter’s 
expression, which in turn, is associated with a higher or lower rate of glycolysis.  GLUT-1 is 
known to be deregulated in several cancers, especially those with high hypoxic rates. 
Besides, GLUT-1 is one of the activated genes in response to the presence of HIF-α in the 
nucleus, which means it is overexpressed in these tumors [82]. In that way, miRNAs that 
directly regulate GLUT-1 can be potentially used as molecular biomarkers for a more 
accurate disease monitorization and an early detection of relapse. Additionally, GLUT-1-
related miRNAs can also bring new possibilities of diagnosis and treatment for cancers with 
high glycolytic rates. Since these miRNAs are considered tumor suppressors, the restorage 
of their levels in cancer cells through the use of exosomes for example, could be an effective 
way to diminish GLUT-1 expression and, consequently, the glucose uptake of the tumor 
Besides, they can also bring new possibilities of diagnosis and treatment through restore of 
their levels [82]. 
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2. OBJECTIVES 
2.1 MAIN OBJECTIVE 
The main goal of the present work was to establish a miRNA expression profile 
associated with the glycolysis status in ccRCC. 
 
2.2 SPECIFIC OBJECTIVES 
• With the purpose of selecting the target molecule of this work and the miRNAs 
involved, a systematic review of literature will be performed.  
• In order to establish a miRNA profile an in vitro study using a normal proximal tubular 
epithelial cell line (HKC-8) and two renal cell carcinoma cell lines (786-O and FG-2) 
will be performed and the levels of the selected miRNAs will be evaluated in these 
cells and in the corresponding culture medium. 
• The influence of the miRNA profile associated with glycolysis will be validated by 
GLUT-1 relative expression quantification, lactate production and metabolic 
capacity measurement. 
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3. MATERIAL AND METHODS 
3.1 CELL LINE CHARACTERIZATION AND MANUTENTION 
Three cell lines were used to perform the present study: HKC-8, 786-O and FG-2. 
The HKC-8 cell line is a human-derived normal renal proximal epithelial tubular cell line 
(Fig. 6A). The 786-O is a renal cell adenocarcinoma cell line derived from a Caucasian 58 
years old man and FG-2 is derived from a 77 years old man and is described as a metastatic 
RCC cell line (Fig 6B and 6C). Both HKC-8 and FG-2 were kindly provided by Dr. Klaas Kok 
from Groningem University (Netherlands) and the 786-O cell line was kindly granted by 
Professor Cármen Jerónimo from the Epigenetics and Cancer Biology Group of CI-IPO-
Porto (Portugal). 
Firstly, a cryopreserved vial of each cell line was thawed. Both 786-O and FG-2 cells 
were kept in RPMI 1640 (1X) medium (Gibco®), supplemented with 10% of FBS (Fetal 
Bovine Serum) (Gibco®) and 1% of Pen-Strep (Gibco®). HKC-8 cells were maintained in 
DMEM/F12 medium (Gibco®), supplemented with ITS (Insulin-transferrine-selenum) 
(Sigma-Aldrich®), Pen-Strep (Gibco®), EGF (Epidermal Growth Factor) (Sigma-Aldrich®), 
Hepes buffer (Gibco®) and Hydrocortisone (Sigma-Aldrich®). The three cell lines were kept 
in an incubator with the following conditions: 37ºC of temperature, 5% CO2 and humid 
atmosphere. 
 
Figure 6 - (A) Microscopic Image (100X) of the HKC-8 cell line. (Photograph taken using an Olympus IX51 
microscope) (B) Microscopic Image of the 786-O cell line (Cell Lines Service © CLS). (C) Microscopic Image of 
the FG-2 cell line. (Cell Lines Service © CLS). 
 
3.2 MicroRNAs SELECTION 
In order to select one of the key glycolysis related molecules to study and, 
consequently, the miRNAs that target it, we wrote a review on the theme. A systematic 
literature search in PubMed was conducted using the keywords or phrases, miRNAs, 
GLUT-1 (Glucose Transporter Type 1), GLUT-4 (Glucose Transporter Type 4), LDHA 
(Lactate Dehydrogenase A), ALDOA (Aldolase A), HK2 (Hexokinase 2), PFK 
(Phosphofructokinase), PGK1 (Phosphoglycerate 1) and SGLT2 (sodium/glucose 
cotransporter 2). The articles were selected by relevance of their findings. All the references 
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of the cited papers were reviewed and relevant publications in the field of metabolism 
involving the molecules studied were added. 
 
3.3 MicroRNA AND mRNA EXTRACTION 
When cells had reached 80-90% confluence, the medium in which they were being 
maintained was collected for miRNA extraction and cells were trypsinized with trypsin-EDTA 
(1X) (Gibco®). Two million cells were counted using the EVE™ Automated Cell Counter 
(NanoEnTek®), centrifuged to form a pellet both for miRNA and mRNA extraction and the 
remaining cells were maintained in culture.  
For each cell line, this procedure was repeated five times, both for the medium and 
for the cells. 
Extraction of miRNA from the cells and the respective medium was then performed 
recurring to the GRS microRNA kit (Grisp®) with a protocol optimized in our lab. Extraction 
of mRNA was performed with the GRS Total- Blood & Cultured Cells kit (Grisp®). 
Concentration and purity of the isolated miRNA and mRNA was then assessed by 
absorbances measurement at 260 and 280nm using the NanoDrop® Lite 
Spectrophotometer.  
 
3.4 cDNA SYNTHESIS AND RELATIVE QUANTIFICATION by REAL-TIME PCR  
MiRNA samples served as templates for cDNA synthesis using a 
Taqman®MicroRNA Reverse Trancription kit (Applied Biosystems®) and sequence-specific 
stem-loop primers for miR-144 and miR-186, RNU44, RNU48 and RNU6b. mRNA samples 
served as templates for complementary DNA (cDNA) synthesis using a High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems®). The thermal conditions for PCR 
amplification were optimized to 16ºC for 30 min, followed by 42ºC for 60 min and 85ºC for 
10 min for miRNAs cDNA synthesis and 25ºC for 10 min, followed by 37ºC for 120 min and 
85ºC for 5 min for mRNA. 
MiRNA and mRNA expression was then assessed by quantitative real-time PCR 
using both StepOneTMqPCR Real-Time PCR machine and StepOnePlusTM qPCR Real-
Time PCR machine. The reaction was performed using 1X Master mix (Applied 
Biosystems®), with 1X probes (TaqMan® microRNA Expression Assays, miR-144*: 
TM002148, miR-186: TM002285, RNU44: TM001094, RNU48: TM001006 and RNU6b: 
TM001093 or TaqMan® mRNA Expression Assays, GLUT-1: Hs00892681_m, human 
GUSB (Beta Glucuronidase) endogenous control (Applied Biosystems®) and cDNA 
sample. The behavior of RNU44, RNU48 and RNU6b expression was analyzed both in 
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medium and inside the cell to understand which one would be the best endogenous control 
for miRNA normalization. GUSB was used as endogenous control to normalize mRNA 
results since its expression levels remained constant. For data analysis, StepOneTM 
Software v2.2 (Applied Biosystems®) was used and the baseline and threshold were set 
for each plate to create threshold cycle (CT) values for all the miRNAs and mRNAs in each 
sample. All quantifications were performed in duplicate and each plate had a negative 
control. Livak method (2-∆∆CT) and t’Student test were used to assess differences between 
the expression levels of the normalized miRNAs and mRNAs (Figure 7) [83]. 
 
 
 
Figure 7 - Schematic representation of miRNA and mRNA quantification protocol. 
 
3.5 LACTATE PRODUCTION AND GLUCOSE CONSUMPTION MEASUREMENT 
180 000 cells were cultured in a 6-multi well plate in the conditions previously 
described. After 72h, the medium in which they were being maintained was collected and 
both lactate production and glucose consumption was measured recurring to GEM Premier 
3000 (Instrumentation Laboratory®).  
To understand the effect of glucose stimulus upon lactate production in the cells, 
upon being cultured, 25mM D-Glucose was added to each plate. Lactate production and 
glucose consumption was then measured using the same mechanism, after 72h. At these 
time points, miRNA and mRNA were extracted and miR-144, miR186, RNU44, RNU48, 
RNU6b, GLUT-1 and GUSB levels were quantified using the protocols described previously. 
Both experiments were performed (six replicates for condition) in HKC-8, 786-O and 
FG-2 cell lines. 
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3.6 METABOLIC CAPACITY MEASUREMENT 
In a 96-multi well plate 10 000 cells were cultured in 8 wells each, 4 of which with 
25mM D-Glucose stimulus. After 24 hours, Resazurin (ACROS Organics®) was added to 
each well in a 10% proportion to the final volume. To calculate the percentage of resazurin 
metabolized, absorbances were then measured at 570 nm and 600 nm using the multi-plate 
reader FLUOstar Omega, BMG Labtech, Offenburg, Germany. This experiment was 
performed in HKC-8, 786-O and FG-2 cell lines. 
To compare the percentage of resazurin metabolized between the three cell lines 
and between cells with and without 25Mm D-Glucose stimulus, the time point chosen 
corresponded to the one when the first cell line reached 100% of resazurin metabolized.   
 
3.7 STATISTICAL ANALYSIS 
Statistical analysis was performed using IBM®SPSS®Statistics for Windows (Version 
20.0). Livak method (2-ΔΔCt) and t´ student test were used to evaluate the differences in the 
expression levels of the normalized miRNAs and mRNAs.  
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4. RESULTS 
4.1 MicroRNAs selection 
Through a systematic revision of literature regarding the glycolysis pathway and the 
miRNAs involved, GLUT-1 was chosen as object of study due to its close relationship with 
RCC, since this transporter is coded by one of the genes whose transcription is induced by 
HIF-α, a key pathway during RCC development. There are several studies reporting the 
regulation of GLUT-1 by 7 different miRNAs in eight different cancer models, including RCC 
(Figure 8; Attachment 1) [84-90].  
 
Figure 8 – Model of miRNAs involved in the aerobic glycolysis in ccRCC pathophysiology. The loss of pVHL 
leads to the accumulation of HIF-α in the nucleus and consequent binding to transcription factors, such as 
GLUT-1. This causes an up-regulation of glucose metabolism in which several miRNAs are involved (adapted 
from Morais M. et al [82]). 
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From the seven miRNAs that were reported to directly target GLUT-1, two were 
chosen: miR-144 and miR-186 (Figure 9). These miRNAs were already associated with 
GLUT-1 deregulation in other tumor models, such as lung cancer and Cancer Associated 
Fibroblasts (CAF) [84, 87].  
 
Figure 9 – Sequences of miR-144 (A) and miR-186 (B) and the potential binding sites at the 3'UTR of GLUT-1 
(adapted from Liu, M. et al and Sun, P. et al [84,87]). 
 
4.2 ENDOGENOUS CONTROL SELECTION  
The graphs represented in figure 10 show the average Ct (the cycle number at which 
the fluorescence generated within a reaction crosses the background fluorescence) of 
RNU44, RNU48 and RNU-6B, both in cells (intracellular) and in culture medium 
(extracellular). The results show that RNU44 is the endogenous control that presents more 
constant average Ct values and smaller standard deviations. As so, RNU44 was the 
endogenous control chosen to normalize the miRNA expression levels in the present study. 
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Figure 10 – Average Ct values of three human miRNAs for endogenous controls across three renal human cell 
lines (A, C and E show the intracellular levels of each miRNA and B, D and F show the extracellular levels of 
each miRNA). 
4.3 MIR-144 AND MIR-186 ARE ASSOCIATED WITH THE WARBURG EFFECT 
Figure 11, 12 and 13 show the graphs representing the intra and extracellular 
relative expression levels of both miR-144 and miR-186 as well as the relative expression 
of mRNA GLUT-1.  
According to the results, there is a significant difference in the intracellular levels of 
miR-144 when comparing HKC-8 and 786-O cell lines, with a reduction of 59% (2-∆∆Ct= 0.41, 
p= 0.028) in the latter. The same tendency is observed between HKC-8 and FG-2 cell lines, 
with a reduction of 63% in the FG-2 cell line (2-∆∆Ct= 0.37, p= 0.069) (Figure 11 – A). 
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Regarding the extracellular levels, the expression of this miRNA is not detected in 
HKC-8 medium but it was detectable in 786-O and FG-2 medium. Both these cell lines 
presented higher extracellular levels of miR-144 when compared with the intracellular ones, 
with a fold-increase of 64 472 in 786-O (p<0.001) and 83 529 in FG-2 (p<0.001) (Figure 11 
– B). 
 
Figure 11 - Variation of the intracellular (A) and extracellular expression levels (B) of miR-144 in HKC-8, 786-O 
and FG-2 (Mean±Std. Error). 
 
Similarly, miR-186 intracellular levels of HKC-8 are significantly different from both 
786-O and FG-2 cell lines, presenting a reduction of 56% (2-∆∆Ct= 0.44, p= 0.010) and 64% 
(2-∆∆Ct= 0.36, p= 0.005) respectively (Figure 12 – A). 
In the three cell lines, the extracellular levels of miR-186 are higher than the 
intracellular ones. There is a 26 fold-increase in HKC-8 (p= 0.001), a 59 fold-increase in 
786-O (p<0.001) and a 174 fold-increase in FG-2 (p<0.001) (Figure 12 – B). 
 
Figure 12 – Variation of the intracellular (A) and extracellular expression levels (B) of miR-186 in HKC-8, 786-
O and FG-2 (Mean±Std. Error). 
 
Regarding the GLUT-1 mRNA relative expression, it is significantly higher in 786-O 
(p<0.001) and FG-2 (p<0.001) when compared with HKC-8 cell line with a 1360 and 1910 
fold-increase, respectively (Figure 13). 
0 
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Figure 13 - Variation of the relative expression levels of GLUT-1 mRNA in HKC-8, 786-O and FG-2 (Mean±Std. 
Error). 
Figure 14 represents the concentration of glucose consumed at the end of 72 hours 
as well as the concentration of lactate produced in the same period for the three cell lines. 
According to the results, consumption of glucose is higher in 786-O (2.1 times, p<0.001) 
and FG-2 cell lines (1.7 times, p<0.001) when compared with HKC-8 cell line (Figure 14 – 
A). Regarding lactate concentration in the cell medium, results show that it is also higher in 
786-O (2.6 times, p<0.001) and FG-2 cell lines (1.64 times, p<0.001) when compared with 
HKC-8 (Figure 14 – B). 
Figure 14 – Variation of glucose consumption (A) and lactate production (B) at the end of 72 hours in HKC-8, 
786-O and FG-2. 
 
Figure 15 shows the graphs describing the metabolic capacity of HKC-8, FG-2 and 
786-O cell lines. The first cell-line to reach the 100% resazurin metabolized was 786-O, 
which happened 5 hours after the addition of the compound (Figure 15 – A). As so, this was 
the time point used to compare the metabolic capacity of the three cell lines. At 5 hours, 
786-O had metabolized significantly more when compared with HKC-8 (100% vs 33%, 
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p<0.001, Figure 15 – B) and the same happened with FG-2 (60% vs 33%, p<0.001, Figure 
15 – B). 
 
Figure 15 – Percentage of resazurin metabolized by 786-O, FG-2 and HKC-8 over time (A); Variation of the 
percentage of resazurin metabolized by HKC-8, 786-O and FG-2, 5hours after the addition of resazurin (B). 
 
4.4 GLUCOSE INTERFERES WITH MIR-144 AND MIR-186 AND GLUT-1 MRNA 
EXPRESSION PATTERN 
 
Figures 16 to 19 show the graphs comparing the basal intra and extracellular levels 
of miR-144 and miR186 as well as the relative expression of GLUT-1 mRNA with the ones 
quantified 72 hours after glucose stimulus for each cell line. 
Regarding HKC-8 cell line, there were no differences neither in the intracellular nor 
in the extracellular levels of miR-144 (p= 0.595 and no detection, respectively, Figure 16 – 
A). However, miR-186 intracellular levels after glucose stimulus are significantly lower than 
the basal ones showing a decrease of 91% (2-∆∆Ct= 0.09, p= 0.006, Figure 16 – B). In 
addition, extracellular levels of this miRNA are also significantly lower after glucose 
stimulus, with a decrease of 79% (2-∆∆Ct= 0.21, p= 0.005, Figure 16 – B). This was 
accompanied by an increase of GLUT-1 mRNA expression (282 fold-change, p<0.001, 
Figure 19).  
 
Figure 16 – Variation of the relative expression levels of miR-144 (A) and miR-186 (B) intracellularly (Cells) and 
extracellularly (Medium) after a 72 hours stimulus with glucose in HKC-8 cell line (Mean±Std. Error). 
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In 786-O cell line there were no differences neither in the intracellular nor the 
extracellular levels of miR-144 (p= 0.315 and p= 0.246, Figure 17 – A). MiR-186 intracellular 
levels after glucose stimulus were not significantly different from the basal ones (p= 0.210, 
Figure 16 – B) as well. However, miR-186 extracellular levels after glucose stimulus were 
significantly higher when compared with the basal levels (4.2 fold-increase, p= 0.034, Figure 
17 – B). This was accompanied by a tendency for an increase of GLUT-1 mRNA expression 
(1.8 increase, p= 0.057, Figure 19). 
 
Figure 17 - Variation of the relative expression levels of miR-144 (A) and miR-186 (B) intracellularly (Cells) and 
extracellularly (Medium) after a 72 hours stimulus with glucose in 786-O cell line (Mean±Std. Error). 
In FG-2 cell line there was no difference between the intracellular levels of miR1-44 
(p= 0.133, Figure 18 - A). However, regarding the extracellular levels of this miRNA, they 
were significantly higher after glucose stimulus (31.8 fold-increase, p= 0.030, Figure 18 – 
A). Similarly, no differences in the intracellular levels of miR-186 after glucose stimulus were 
observed (p= 0.113, Figure 18 – B). But, like before, the extracellular levels of miR-186 after 
glucose stimulus were significantly higher (7.11 fold increase, p= 0.044, Figure 18 – B). This 
was accompanied by an increase of GLUT-1 mRNA expression (1.9 fold-increase, p<0.001, 
Figure 19). 
 
Figure 18 - Variation of the relative expression levels of miR-144 (A) and miR-186 (B) intracellularly (Cells) and 
extracellularly (Medium) after a 72 hours stimulus with glucose in FG-2 cell line (Mean±Std. Error). 
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Figure 19 - Variation of the relative expression levels of GLUT-1 mRNA after a 72 hours stimulus with glucose 
in HKC-8, 786-O and FG-2 cell lines (Mean±Std. Error). 
Figure 20 represents the concentration of glucose consumed 72 hours after the 
glucose stimulus, when compared with its basal consumption. In addition, it represents the 
concentration of lactate produced after the same period, comparing it with its basal 
production. 
After glucose stimulus, 786-O and FG-2 cell lines show a decrease of consumption 
when compared with the respective controls (13%, p= 0.004 and 13%, p= 0.016, 
respectively, Figure 20 – A). The amount of glucose in HKC-8 after glucose stimulus was 
impossible to quantify since it was higher than the range of the equipment. Regarding 
lactate concentration, results show that, in the three lines, it is lower after glucose stimulus, 
when compared with the control ones. HKC-8 shows a reduction of 8% (p<0.001), 786-O 
shows a reduction of 13% (p<0.001) and FG-2 shows a reduction of 13% (p= 0.003). 
However, lactate concentration is still higher in 786-O and FG-2 when compared with HKC-
8 (Figure 20 – B). 
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Figure 20 - Variation of glucose consumption (A) and lactate production (B) at the end of a 72 hours glucose 
stimulus in HKC-8, 786-O and FG-2. 
    
Figure 21 shows the graph describing the metabolic capacity of HKC-8, FG-2 and 
786-O cell lines, after a 24-hour glucose stimulus. Since without any stimulus, 786-O had 
reached the 100% of metabolized resazurin after 5 hours, this was the time point used to 
compare the metabolic capacity of the three cell lines. Both HKC-8 and 786-O did not show 
any differences with the glucose stimulus (p=0.108 and p=0.089, respectively) but 786-O 
had metabolized significantly less after the glucose stimulus (100% vs 80%, p<0.001, Figure 
22). 
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Figure 21 - Variation of the percentage of resazurin metabolized without (control) and with a 24-hour glucose 
stimulus (Glucose) by HKC-8, 786-O and FG-2, 5 hours after the addition of resazurin. 
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5. DISCUSSION 
Since 2011, the deregulation of cellular metabolism is considered one Hallmark of 
Cancer but these alterations have been object of study for a long time [13]. Glucose 
metabolism is altered in many ways to maximize the production of energy and of new  
building blocks [18]. One of the first deregulation mechanisms reported was the so-called 
Warburg Effect, or aerobic glycolysis, in which cells prefer to metabolize glucose through 
glycolysis followed by lactic fermentation instead of oxidative phosphorylation, even in the 
presence of oxygen. Despite having been first described in 1920s, and having already been 
observed in many tumor models, including the RCC, the selective advantage of this effect 
is not yet fully understood [19].  
Warburg effect depends on the disruption of several signaling pathways and on the 
deregulation of the expression of both metabolic enzymes and transport systems, namely 
the GLUT-1 transporter [29]. Its upregulation, which is reported in RCC, leads to a greater 
uptake of glucose by cancer cells that is necessary to surpass the difference of ATP 
obtained by aerobic glycolysis instead of oxidative phosphorylation. Besides, GLUT-1 
transporter is reported as upregulated in ccRCC and its gene transcription is known to be 
induced by HIF-α [51]. Because of that, GLUT-1 has a great relevance in the establishment 
of the Warburg Effect in RCC. These mechanisms are very complex and there are still many 
things about them that remain unclarified. Contributing to this complexity, miRNAs are 
currently appointed as key elements in Warburg Effect, influencing its establishment [82].  
The coding sequence of miR-144 is located in chromosome 17q11.2 and several 
studies report its deregulation in various tumor models, such as bladder cancer, gastric 
cancer and lung cancer [84, 91-93]. In ccRCC two studies reported a downregulation in 
cancer cell lines, when compared with non-cancerous tissues or HK-2, a normal epithelial 
kidney cell line [94, 95]. These results are consistent with what was observed in the present 
study, since 786-O had a miR-144 intracellular level’s reduction of 59% (p=0.028) when 
comparing with HKC-8. Moreover, we also observed a tendential reduction of 63% 
(p=0,069) of its expression in FG-2 cell line (another ccRCC cell line, defined with an 
aggressive behavior), which corroborates the downregulation of miR-144 in ccRCC cells. 
However, there are still no studies reporting miR-144 extracellular expression in 
RCC. In fact, we were not able to detect it in HCK-8’s medium but we detected it in both 
tumor cell lines, which may suggest the secretion of miR-144 only occurs in cancer cells. 
Ning Lou and co-workers reported miR144 as a possible biomarker of diagnosis for ccRCC, 
since it was up-regulated in the plasma of patients with this cancer [96] This study also 
reported miR-144 as up-regulated in ccRCC tissues. However, Xiang and colleagues 
describe it as down-regulated, showing that the role of this miRNA is still not completely 
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understood [95]. Taking this data into account, we hypothesize that in addition to a decrease 
in miR-144 production by ccRCC cancer cells, the cells may also start to excrete this miRNA 
to the cellular microenvironment, which can potentiate an advantage for tumor progression. 
The coding sequence of miR-186 is located in chromosome 1p31.1 and its 
deregulation has been reported in many tumor models [97]. MiR-186 is said to be 
downregulated in several types of cancer such as prostate, non-small cell lung, gastric or 
hepatocellular carcinoma [98-101]. In RCC, one study has reported a downregulation in 
cancer cell lines, namely 786-O, when comparing with HKC-2 [102]. This result is consistent 
with what was observed in the present study since 786-O had a significantly lower level of 
miR-186 when compared with HKC-8 (56%, p= 0.010). We also observed a decrease in 
miR-186 expression level in FG-2 cell line (64%, p= 0.005). Regarding miR-186 levels in 
the extracellular medium, there are still no studies, neither in vitro nor in vivo. In our study, 
we found an increase in miR-186 extracellular expression, when compared with the 
intracellular one in the three cell lines studied (HKC-8, 786-O and FG-2, p<0.001). However, 
both 786-O and FG-2 presented a greater fold change increase when compared with HKC-
8. As so, what we propose is that, besides a decrease in miR-186 production by RCC cancer 
cell lines, there is also an increase of this miRNA excretion, as an attempt by the cell to free 
itself from it and like this sustain a high glycolytic rate. 
Both miR-144 and miR-186 have been implied to directly target GLUT-1 mRNA in 
lung cancer and in CAF formation, respectively [84, 87]. In our study, GLUT-1 was 
significantly increased in both RCC cell lines when compared with the normal renal cell line. 
This was accompanied by an increase in glucose consumption and an increase in lactate 
production. 
What we propose is that in RCC there is a decrease in miR-144 and miR-186 
production accompanied by an increase of their excretion. Several studies have shown a 
global suppression in miRNAs biogenesis due to lower levels miRNA processing machinery 
components [64]. Yang Fan and co-workers stated that DICER expression was 
downregulated in ccRCC and could be a potential prognostic factor [103]. This suppression 
of miRNA biogenesis can possibly explain the decrease of miR-144 and miR-186 production 
in RCC.  
The first miRNA profiling of human plasma/serum was only completed in 2008 and 
since then many questions arose about these miRNAs [104]. Since miRNAs’ biogenesis 
occurs inside the cell, extracellular miRNAs must be exported into circulation. The transport 
of miRNAs in the extracellular medium has been reported to be done by membrane-derived 
vesicles, lipoproteins, ribonucleoprotein complexes, exosomes, microparticles, lipoproteins 
and viral surface antigen particles [105]. There is still not much known about why miRNAs 
are exported but cells seem to actively secrete specific miRNAs in response to cellular 
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signals or environmental stimulus. The fact that some miRNAs appear to be produced only 
to be excreted, that some signaling pathways have been related with miRNAs release and 
that miRNAs profiles of extracellular vesicles are not representative of their parent cells 
supports this selectivity theory [105]. The increase of miR-144 and miR-186 excretion in 
RCC, observed in our study, may be supported by this selectivity.  In addition, we 
hypothesize that it can come as a pro-tumoral response by the RCC cells since by 
discarding these miRNAs they can promote GLUT-1 expression.    
Since miR-144 and miR-186 target GLUT-1, their deregulation is responsible for an 
upregulation of GLUT-1’s expression leading to a higher glucose consumption. This higher 
glucose consumption is needed to make up for the less energy obtained in the deviation of 
glucose metabolism into aerobic glycolysis, which is proven by the increased rate of 
metabolic capacity and by the increase of lactate production (Figure 29).   
 
Figure 19 – Proposed model of miR-144 and miR-186 role during RCC development, according to the results 
obtained in the present study. 
In order to clarify the effect of glucose consumption in the cell, we gave an acute 
glucose stimulus to all the cell lines. We verified a reduction of both miR-186 production 
and excretion, accompanied by an increase of GLUT-1 mRNA in the HKC-8 cell line. We 
believe the reduction of the extracellular level of this miRNA is a simple reflection of its 
diminished production and that the decrease of production lead to the great increase of 
GLUT-1’s mRNA levels in the HKC-8 cell line.  
In the two RCC cell lines, despite the unaltered production of both miRNAs, we 
observed a statistical increase of miR-186 (p= 0.034 in 786-O and p= 0,034 in FG-2) and 
of miR-144 excretion (p= 0.044 in FG-2) after glucose stimulus. This increase of miR-144 
and miR-186 excretion was followed by an increase of GLUT-1 mRNA levels, which is 
consistent with the hypothesis that we proposed above about the importance of these 
miRNAs in GLUT-1 regulation.  
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Additionally, these results, either in normal and in tumor cell lines, show the power 
a single stimulus from the microenvironment has epigenetically, since it was enough to 
trigger epigenetic mechanisms (miRNAs production inhibition and miRNAs excretion) that 
would lead to a better availability of GLUT-1. 
Interestingly, we observed that the acute glucose stimulus also resulted in lower 
glucose consumption, slower metabolic capacity (only in 786-O cell line) and, a consequent 
lower lactate production. We hypothesize that the reduction of glucose consumption may 
be due to a solute saturation of the cell medium and a consequent increased osmotic 
pressure that reduces the entrance of glucose. However, it is important to note that the 
decrease rate of glucose consumption in 786-O and FG-2 cell lines was equal to the 
decrease rate of lactate production (~13%), which supports the Warburg Effect, since the 
glucose that enters these cells seems to be mainly used for aerobic glycolysis. 
Nevertheless, further studies are needed to validate these hypotheses.  
The results of the present study demonstrate the importance of the miR-144 and 
miR-186 both in the regulation of glucose metabolism and their potential use as aerobic 
glycolysis biomarkers.  
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6. CONCLUSION AND FUTURE PERSPECTIVES 
 
The lack of a standard screening test for an early detection as well as the absence 
of accurate follow-up biomarkers are the main reasons why RCC is the most lethal 
urological neoplasia. 
One of the most important regulators of gene expression are miRNAs: small non-
coding RNAs that regulate mRNA's expression at a post-transcriptional level. MiRNAs 
present different expression patterns in normal and tumoral tissues and are able to identify 
a disease before any symptomatic manifestation. Besides, they are highly stable and easy 
to detect, whether in cells or other biological fluids, simply by recurring to a blood or urine 
sample. Therefore, setting miRNAs expression patterns may lead to the identification of 
possible biomarkers of diagnosis, prognosis and therapy response, since the expression 
levels of specific miRNAs may differ accordingly to these parameters.  
The Warburg Effect has been described to happen in several cancers including the 
RCC. This metabolic switch is driven by the deregulation of several signaling pathways and 
metabolic enzymes, proteins and transporters, including GLUT-1. In RCC, GLUT-1 has an 
increased relevance since this transporter’s gene is one of whose transcription is induced 
by the accumulation of HIF-α in the nucleus. As so, GLUT-1 may play a central part in the 
metabolic switch that occurs in RCC. 
In this study, we have found that miR-144 and miR-186’s expression is deregulated 
in RCC. This is accompanied by an increase of GLUT-1 mRNA expression, an increase of 
glucose consumption and a higher production of lactate. Summing up, the deregulation of 
both miR-144 and miR-186 seems to have a role in the switch of cancer cells to Warburg 
Effect. This deregulation seems to be established not only by a decrease in the production 
of miR-144 and miR-186 but also by an increase of its excretion. This increase of excretion 
appears to be selective to certain miRNAs depending on their effect on the cells. Moreover, 
we also found that this deregulation aggravates with an environmental stimulus (in this case 
with glucose), not only in cancer cells but also in the normal ones, showing the power of 
environment in epigenetics regulation. 
The deregulation of these miRNAs’ excretion defines them as possible circulating 
miRNAs and offers the possibility to use both of them as potential biomarkers not only of 
diagnosis but possibly, of prognosis and follow-up. This may help to fill the void of good 
biomarkers enabling the construction of efficient screening tests for RCC.  
This study naturally presents some limitations. Being an in vitro study, it would be 
important to replicate it in vivo, in order to validate the results obtained so that these miRNAs 
may potentially be used in the future as standard biomarkers. A case-control study, using 
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plasma samples, would be useful to understand if the expression levels of both miRNAs in 
patients with RCC are different from healthy individuals. In this study, it would also be useful 
to understand what are the differences in the miRNAs expression levels of RCC patients 
accordingly to their histopathological and clinical characteristics. This would help to clarify 
the role of these miRNAs as possible biomarkers of diagnosis, prognosis or follow-up. It 
would also be interesting to use the corresponding tumor samples in order to complement 
the relation between intra and extracellular levels explored in the in vitro study. Additionally, 
we believe that in order to improve the miRNA profile we proposed, it would be important to 
study more miRNAs that may be potentially deregulated in RCC. As so, in the future, we 
would like to study miRNAs that directly target other transporters expressed in renal cells 
or glycolytic enzymes.  
The results of the experiment conducted with the glucose stimulus are promising but 
somehow unexpected. Therefore, in the future, we would like to replicate them adding up 
other conditions that would help us strengthen these results. We believe it would be 
interesting to understand the evolution of miR-144 and miR-186 expression levels and also 
of glucose consumption and lactate production after stimulus with different concentrations 
of glucose. It would also be important to add up more measure points (not only after 72 
hours, but also after 24 and even 96 hours). Finally, we would like to understand if there is 
any difference in cells response to a chronical stimulus, in opposition to the acute one we 
tested. 
Regarding the mechanisms of decrease in miRNA’s production it would be 
interesting to evaluate if there are any differences in the expression of the enzymes involved 
in miRNAs biogenesis, such as DICER or Exportin 5, for example. Since these miRNAs 
potential seems to lay in their extracellular expression, in the future, it would be important 
to improve the existing knowledge about miRNAs excretion pathways. As so, we would like 
to study these pathways, how are they altered in RCC and in which ways they are regulated 
in order to favor a selectivity prone to the tumor. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
References 
 
GLUT-1-related microRNAs and the Glycolysis in Clear Cell Renal Cell Carcinoma 
75 
 
7. REFERENCES 
1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2016. CA Cancer J Clin, 
2016. 66(1): p. 7-30. 
2. Torre, L.A., et al., Global cancer statistics, 2012. CA Cancer J Clin, 2015. 65(2): p. 
87-108. 
3. Ferlay, J., et al., Cancer incidence and mortality patterns in Europe: estimates for 
40 countries in 2012. Eur J Cancer, 2013. 49(6): p. 1374-403. 
4. Jemal, A., et al., Global cancer statistics. CA Cancer J Clin, 2011. 61(2): p. 69-90. 
5. Ferlay, J., et al., Cancer incidence and mortality worldwide: sources, methods and 
major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359-86. 
6. RORENO. Registo Oncológico Regional do Norte 2011. Instituto Português de 
Oncologia do Porto, ed.. Porto, 2017. 
7. RORENO. Projeções da incidência de cancro na Região Norte - 2013, 2015 e 2020. 
Instituto Português de Oncologia do Porto, ed. Porto, 2013. 
 
8. DeVita, L., Lawrence, T., Rosenberg,S., Cancer: Principles & Practice of Oncology. 
8th ed. 2008: Lippincott Williams & Wilkins. 
9. Abbas, K., Mitchell, F., Robbins Basic Pathology. 8th ed. 2007: Saunders Elsevier. 
10. Strahm, B. and M. Capra, Insights into the molecular basis of cancer development. 
Current Paediatrics. 15(4): p. 333-338. 
11. Pitot, H.C., The molecular biology of carcinogenesis. Cancer, 1993. 72(3 Suppl): p. 
962-70. 
12. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 57-
70. 
13. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 
2011. 144(5): p. 646-74. 
14. Yang, H., Y. Xiong, and K. Guan, Metabolic alteration in tumorigenesis. Sci China 
Life Sci, 2013. 56(12): p. 1067-75. 
15. Boroughs, L.K. and R.J. DeBerardinis, Metabolic pathways promoting cancer cell 
survival and growth. Nat Cell Biol, 2015. 17(4): p. 351-9. 
16. Robey, R.B., et al., Metabolic reprogramming and dysregulated metabolism: cause, 
consequence and/or enabler of environmental carcinogenesis? Carcinogenesis, 
2015. 36 Suppl 1: p. S203-31. 
References 
 
GLUT-1-related microRNAs and the Glycolysis in Clear Cell Renal Cell Carcinoma 
76 
17. Cha, Y.H., et al., Catabolic metabolism during cancer EMT. Arch Pharm Res, 2015. 
38(3): p. 313-20. 
18. Li, Z. and H. Zhang, Reprogramming of glucose, fatty acid and amino acid 
metabolism for cancer progression. Cell Mol Life Sci, 2016. 73(2): p. 377-92. 
19. O. Warburg, The metabolism of carcinoma cells, Cancer Res. 9 (1925) 148–163. 
20. Macheda, M.L., S. Rogers, and J.D. Best, Molecular and cellular regulation of 
glucose transporter (GLUT) proteins in cancer. J Cell Physiol, 2005. 202(3): p. 654-
62. 
21. Oermann, E.K., et al., Alterations of Metabolic Genes and Metabolites in Cancer. 
Semin Cell Dev Biol, 2012. 23(4): p. 370-80. 
22. Xu, W., et al., Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-
ketoglutarate-dependent dioxygenases. Cancer Cell, 2011. 19(1): p. 17-30. 
23. Dong, X., et al., Glucose metabolism gene polymorphisms and clinical outcome in 
pancreatic cancer. Cancer, 2011. 117(3): p. 480-91. 
24. Lyu, Z., et al., Genetic variants in glucose-6-phosphate isomerase gene as 
prognosis predictors in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol, 
2016. 40(6): p. 698-704. 
25. Page, T., et al., Glucose transporter polymorphisms are associated with clear-cell 
renal carcinoma. Cancer Genet Cytogenet, 2005. 163(2): p. 151-5. 
26. Koppenol, W.H., P.L. Bounds, and C.V. Dang, Otto Warburg's contributions to 
current concepts of cancer metabolism. Nat Rev Cancer, 2011. 11(5): p. 325-37. 
27. Vander Heiden, M.G., L.C. Cantley, and C.B. Thompson, Understanding the 
Warburg effect: the metabolic requirements of cell proliferation. Science, 2009. 
324(5930): p. 1029-33. 
28. Devic S. Warburg Effect - a Consequence or the Cause of Carcinogenesis?. J 
Cancer 2016; 7(7):817-822. doi:10.7150/jca.14274. 
29. Cairns, R.A., Drivers of the Warburg phenotype. Cancer J, 2015. 21(2): p. 56-61. 
30. Ganapathy, V., M. Thangaraju, and P.D. Prasad, Nutrient transporters in cancer: 
relevance to Warburg hypothesis and beyond. Pharmacol Ther, 2009. 121(1): p. 29-
40. 
31. Racker, E., Bioenergetics and the problem of tumor growth. Am Sci, 1972. 60(1): p. 
56-63. 
32. Slavov, N., et al., Constant growth rate can be supported by decreasing energy flux 
and increasing aerobic glycolysis. Cell Rep, 2014. 7(3): p. 705-14. 
References 
 
GLUT-1-related microRNAs and the Glycolysis in Clear Cell Renal Cell Carcinoma 
77 
33. Shlomi, T., et al., Genome-scale metabolic modeling elucidates the role of 
proliferative adaptation in causing the Warburg effect. PLoS Comput Biol, 2011. 
7(3): p. e1002018. 
34. Liberti, M.V. and J.W. Locasale, The Warburg Effect: How Does it Benefit Cancer 
Cells? Trends Biochem Sci, 2016. 41(3): p. 211-8. 
35. Escudier, B., et al., Renal cell carcinoma: ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up. Ann Oncol, 2016. 27(suppl 5): p. v58-v68. 
36. Hsieh, J.J., et al., Renal cell carcinoma. Nat Rev Dis Primers, 2017. 3: p. 17009. 
37. Chow, W.H., L.M. Dong, and S.S. Devesa, Epidemiology and risk factors for kidney 
cancer. Nat Rev Urol, 2010. 7(5): p. 245-57. 
38. Ljungberg, B., et al., EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol, 
2015. 67(5): p. 913-24. 
39. Patard, J.J., et al., ICUD-EAU International Consultation on Kidney Cancer 2010: 
treatment of metastatic disease. Eur Urol, 2011. 60(4): p. 684-90. 
40. Kim, S.P., et al., Independent validation of the 2010 American Joint Committee on 
Cancer TNM classification for renal cell carcinoma: results from a large, single 
institution cohort. J Urol, 2011. 185(6): p. 2035-9. 
41. Choueiri, T.K. and R.J. Motzer, Systemic Therapy for Metastatic Renal-Cell 
Carcinoma. N Engl J Med, 2017. 376(4): p. 354-366. 
42. Bielecka, Z.F., et al., Mechanisms of Acquired Resistance to Tyrosine Kinase 
Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). Curr Signal Transduct Ther, 
2014. 8(3): p. 218-228. 
43. Moch, H., et al., The 2016 WHO Classification of Tumours of the Urinary System 
and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 
2016. 70(1): p. 93-105. 
44. Smaldone, M.C. and J.K. Maranchie, Clinical implications of hypoxia inducible factor 
in renal cell carcinoma. Urol Oncol, 2009. 27(3): p. 238-45. 
45. Dias, F., et al., Renal cell carcinoma development and miRNAs: a possible link to 
the EGFR pathway. Pharmacogenomics, 2013. 14(14): p. 1793-803. 
46. Haase, V.H., The VHL Tumor Suppressor: Master Regulator of HIF. Curr Pharm 
Des, 2009. 15(33): p. 3895-903. 
47. Sang, N., et al., Carboxyl-terminal transactivation activity of hypoxia-inducible factor 
1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-
regulated association with p300/CBP. Mol Cell Biol, 2002. 22(9): p. 2984-92. 
References 
 
GLUT-1-related microRNAs and the Glycolysis in Clear Cell Renal Cell Carcinoma 
78 
48. Ohh, M., et al., Ubiquitination of hypoxia-inducible factor requires direct binding to 
the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol, 2000. 2(7): p. 423-
7. 
49. Baldewijns, M.M., et al., VHL and HIF signalling in renal cell carcinogenesis. J 
Pathol, 2010. 221(2): p. 125-38. 
50. Audenet, F., et al., Genetic pathways involved in carcinogenesis of clear cell renal 
cell carcinoma: genomics towards personalized medicine. BJU Int, 2012. 109(12): 
p. 1864-70. 
51. Schodel, J., et al., Hypoxia, Hypoxia-inducible Transcription Factors, and Renal 
Cancer. Eur Urol, 2016. 69(4): p. 646-57. 
52. Rathmell, W.K. and S. Chen, VHL inactivation in renal cell carcinoma: implications 
for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther, 2008. 8(1): p. 
63-73. 
53. Ravaud, A. and M. Gross-Goupil, Overcoming resistance to tyrosine kinase 
inhibitors in renal cell carcinoma. Cancer Treat Rev, 2012. 38(8): p. 996-1003. 
54. Ravaud, A., et al. (2010). "Treatment Strategies in Metastatic Renal Cell 
Carcinoma." European Oncology 6(2): 41-46. 
55. Strimbu, K. and J.A. Tavel, What are Biomarkers? Curr Opin HIV AIDS, 2010. 5(6): 
p. 463-6. 
56. Weber, J.A., et al., The microRNA spectrum in 12 body fluids. Clin Chem, 2010. 
56(11): p. 1733-41. 
57. Teixeira, A.L., et al., Circulating biomarkers in renal cell carcinoma: the link between 
microRNAs and extracellular vesicles, where are we now? J Kidney Cancer VHL, 
2014. 1(8): p. 84-98. 
58. Li, M., et al., MicroRNAs in renal cell carcinoma: A systematic review of clinical 
implications (Review). Oncol Rep, 2015. 33(4): p. 1571-8. 
59. Al-Ali, B.M., et al., MicroRNAs in renal cell carcinoma: implications for pathogenesis, 
diagnosis, prognosis and therapy. Anticancer Res, 2012. 32(9): p. 3727-32. 
60. Gowrishankar, B., et al., MicroRNA expression signatures of stage, grade, and 
progression in clear cell RCC. Cancer Biol Ther, 2014. 15(3): p. 329-41. 
61. Gu, L., et al., MicroRNAs as prognostic molecular signatures in renal cell carcinoma: 
a systematic review and meta-analysis. Oncotarget, 2015. 6(32): p. 32545-60. 
62. Hayes, J., P.P. Peruzzi, and S. Lawler, MicroRNAs in cancer: biomarkers, functions 
and therapy. Trends Mol Med, 2014. 20(8): p. 460-9. 
References 
 
GLUT-1-related microRNAs and the Glycolysis in Clear Cell Renal Cell Carcinoma 
79 
63. Tutar, L., et al., Therapeutic Targeting of microRNAs in Cancer: Future 
Perspectives. Drug Dev Res, 2015. 76(7): p. 382-8. 
64. Lin, S. and R.I. Gregory, MicroRNA biogenesis pathways in cancer. Nat Rev Cancer, 
2015. 15(6): p. 321-33. 
65. Bhatt, K., Q.S. Mi, and Z. Dong, microRNAs in kidneys: biogenesis, regulation, and 
pathophysiological roles. Am J Physiol Renal Physiol, 2011. 300(3): p. F602-10. 
66. Wei, Q., Q.S. Mi, and Z. Dong, The regulation and function of microRNAs in kidney 
diseases. IUBMB Life, 2013. 65(7): p. 602-14. 
67. Tang, K. and H. Xu, Prognostic value of meta-signature miRNAs in renal cell 
carcinoma: an integrated miRNA expression profiling analysis. Sci Rep, 2015. 5: p. 
10272. 
68. Chen, X., et al., Characterization of microRNAs in serum: a novel class of 
biomarkers for diagnosis of cancer and other diseases. Cell Res, 2008. 18(10): p. 
997-1006. 
69. Teixeira, A.L., M. Gomes, and R. Medeiros, EGFR signaling pathway and related-
miRNAs in age-related diseases: the example of miR-221 and miR-222. Front 
Genet, 2012. 3. 
70. Wulfken, L.M., et al., MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications 
of Serum miR-1233 Levels. PLoS One, 2011. 6(9). 
71. Duns, G., et al., The entire miR-200 seed family is strongly deregulated in clear cell 
renal cell cancer compared to the proximal tubular epithelial cells of the kidney. 
Genes Chromosomes Cancer, 2013. 52(2): p. 165-73. 
72. Youssef, Y.M., et al., Accurate molecular classification of kidney cancer subtypes 
using microRNA signature. Eur Urol, 2011. 59(5): p. 721-30. 
73. Shuch, B., W.M. Linehan, and R. Srinivasan, Aerobic Glycolysis: A Novel Target in 
Kidney Cancer. Expert Rev Anticancer Ther, 2013. 13(6): p. 711-9. 
74. Comprehensive molecular characterization of clear cell renal cell carcinoma. 
Nature, 2013. 499(7456): p. 43-9. 
75. List, J.F. and J.M. Whaley, Glucose dynamics and mechanistic implications of 
SGLT2 inhibitors in animals and humans. Kidney Int Suppl, 2011(120): p. S20-7. 
76. Chan, D.A., Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by 
Chemical Synthetic Lethality. 2011. 3(94): p. 94ra70. 
77. Soltysova, A., et al., Deregulation of energetic metabolism in the clear cell renal cell 
carcinoma: A multiple pathway analysis based on microarray profiling. Int J Oncol, 
2015. 47(1): p. 287-95. 
References 
 
GLUT-1-related microRNAs and the Glycolysis in Clear Cell Renal Cell Carcinoma 
80 
78. Lin, C.S., et al., Role of Mitochondrial DNA Copy Number Alteration in Human Renal 
Cell Carcinoma. Int J Mol Sci, 2016. 17(6). 
79. Neely, B.A., et al., Proteotranscriptomic Analysis Reveals Stage Specific Changes 
in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma. PLoS One, 2016. 
11(4): p. e0154074. 
80. Wang, X., et al., Inhibition of LDHA Deliver Potential Anticancer Performance in 
Renal Cell Carcinoma. Urol Int, 2017. 99(2): p. 237-244. 
81. Kuang, H., et al., Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor 
Dapagliflozin on Renal Cell Carcinoma. Med Sci Monit, 2017. 23: p. 3737-3745. 
82. Morais, M., et al., MicroRNAs and altered metabolism of clear cell renal cell 
carcinoma: Potential role as aerobic glycolysis biomarkers. Biochim Biophys Acta, 
2017. 1861(9): p. 2175-2185. 
83. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 
25(4): p. 402-8. 
84. Liu, M., et al., Downregulating microRNA-144 mediates a metabolic shift in lung 
cancer cells by regulating GLUT1 expression. Oncol Lett, 2016. 11(6): p. 3772-3776. 
85. Nie, S., et al., miR-495 mediates metabolic shift in glioma cells via targeting Glut1. 
J Craniofac Surg, 2015. 26(2): p. e155-8. 
86. Qu, W., et al., miR-132 mediates a metabolic shift in prostate cancer cells by 
targeting Glut1. FEBS Open Bio, 2016. 6(7): p. 735-41. 
87. Sun, P., et al., miR-186 regulates glycolysis through Glut1 during the formation of 
cancer-associated fibroblasts. Asian Pac J Cancer Prev, 2014. 15(10): p. 4245-50. 
88. Xu, P., et al., MicroRNA-340 Mediates Metabolic Shift in Oral Squamous Cell 
Carcinoma by Targeting Glucose Transporter-1. J Oral Maxillofac Surg, 2016. 74(4): 
p. 844-50. 
89. Chen, B., et al., miR-22 as a prognostic factor targets glucose transporter protein 
type 1 in breast cancer. Cancer Lett, 2015. 356(2 Pt B): p. 410-7. 
90. Yamasaki, T., et al., Tumor-suppressive microRNA-1291 directly regulates glucose 
transporter 1 in renal cell carcinoma. Cancer Sci, 2013. 104(11): p. 1411-9. 
91. Doss, J.F., et al., A comprehensive joint analysis of the long and short RNA 
transcriptomes of human erythrocytes. BMC Genomics, 2015. 16. 
92. Matsushita, R., et al., Tumour-suppressive microRNA-144-5p directly targets 
CCNE1/2 as potential prognostic markers in bladder cancer. Br J Cancer, 2015. 
113(2): p. 282-9. 
References 
 
GLUT-1-related microRNAs and the Glycolysis in Clear Cell Renal Cell Carcinoma 
81 
93. Ren, K., et al., MiR-144 functions as tumor suppressor by targeting PIM1 in gastric 
cancer. Eur Rev Med Pharmacol Sci, 2017. 21(13): p. 3028-3037. 
94. Liu, F., et al., miR-144-3p serves as a tumor suppressor for renal cell carcinoma and 
inhibits its invasion and metastasis by targeting MAP3K8. Biochem Biophys Res 
Commun, 2016. 480(1): p. 87-93. 
95. Xiang, C., S.P. Cui, and Y. Ke, MiR-144 inhibits cell proliferation of renal cell 
carcinoma by targeting MTOR. J Huazhong Univ Sci Technolog Med Sci, 2016. 
36(2): p. 186-92. 
96. Lou, N., et al., miR-144-3p as a novel plasma diagnostic biomarker for clear cell 
renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations. 
35(1): p. 36.e7-36.e14. 
97. Cai, J., et al., miR-186 downregulation correlates with poor survival in lung 
adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res, 2013. 
73(2): p. 756-66. 
98. Lu, S., et al., miRNA-186 inhibits prostate cancer cell proliferation and tumor growth 
by targeting YY1 and CDK6. Exp Ther Med, 2017. 13(6): p. 3309-3314. 
99. Huang, T., et al., MicroRNA-186 suppresses cell proliferation and metastasis 
through targeting MAP3K2 in non-small cell lung cancer. Int J Oncol, 2016. 49(4): 
p. 1437-44. 
100. Liu, L., et al., MiR-186 inhibited aerobic glycolysis in gastric cancer via HIF-1alpha 
regulation. Oncogenesis, 2016. 5: p. e224. 
101. Ruan, T., et al., MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo 
signaling and tumorigenesis in hepatocellular carcinoma. Oncol Lett, 2016. 11(4): p. 
2941-2945. 
102. Jiao, D., et al., microRNA-186 Suppresses Cell Proliferation and Metastasis 
Through Targeting Sentrin Specific Protease 1 in Renal Cell Carcinoma. Oncol Res, 
2017. 
103. Fan, Y., et al., Dicer suppresses the malignant phenotype in VHL-deficient clear cell 
renal cell carcinoma by inhibiting HIF-2α. Oncotarget, 2016. 7(14): p. 18280-94. 
104. Lawrie, C.H., et al., Detection of elevated levels of tumour-associated microRNAs in 
serum of patients with diffuse large B-cell lymphoma. Br J Haematol, 2008. 141(5): 
p. 672-5. 
105. Boon, R.A. and K.C. Vickers, Intercellular transport of microRNAs. Arterioscler 
Thromb Vasc Biol, 2013. 33(2): p. 186-92. 
 
 
 
References 
 
GLUT-1-related microRNAs and the Glycolysis in Clear Cell Renal Cell Carcinoma 
82 
 
 
 
  
 
 
  
 
 
  	

MicroRNAs and altered metabolism of Clear Cell Renal Cell Carcinoma:
Potential role as aerobic glycolysis biomarkers
Mariana Morais, Francisca Dias, Ana L. Teixeira, Rui Medeiros
PII: S0304-4165(17)30186-1
DOI: doi:10.1016/j.bbagen.2017.05.028
Reference: BBAGEN 28855
To appear in: BBA - General Subjects
Received date: 28 December 2016
Revised date: 9 May 2017
Accepted date: 30 May 2017
Please cite this article as: Mariana Morais, Francisca Dias, Ana L. Teixeira,
Rui Medeiros, MicroRNAs and altered metabolism of Clear Cell Renal Cell Carci-
noma: Potential role as aerobic glycolysis biomarkers, BBA - General Subjects (2017),
doi:10.1016/j.bbagen.2017.05.028
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 1 
MicroRNAs and altered metabolism of Clear Cell Renal Cell Carcinoma: Potential 
role as aerobic glycolysis biomarkers 
 
Mariana Morais
1,2#
, Francisca Dias
1,2,3#
, Ana L Teixeira
1,3*
 and Rui Medeiros
1,3,4,5* 
 
 
1
Molecular Oncology & Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese 
Oncology Institute of Porto (IPO-Porto), Porto, Portugal 
2
ICBAS, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Portugal  
3
Research Department, LPCC- Portuguese League, Against Cancer (NRNorte), Porto, Portugal 
4
CEBIMED, Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal  
5
FMUP, Faculty of Medicine, University of Porto, Portugal 
 
# These authors contributed equally to this work 
 
 
 
 
 
* Correspondance should be addressed to 
A.L.T.:  ana.luisa.teixeira@ipoporto.min-saude.pt 
R.M.: ruimedei@ipoporto.min-saude.pt 
Molecular Oncology & Viral Pathology Group 
Portuguese Oncology Institute of Porto  
Rua Dr. António Bernardino de Almeida 
4200-072 Porto, Portugal  
Phone: 351- 22 508 4000 (ext: 5414) 
Fax: 351- 22 508 4001 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 2 
Abstract 
 
BACKGROUND: Warburg Effect is a metabolic switch that occurs in most of cancer cells but 
its advantages are not fully understood. This switch is known to happen in renal cell carcinoma 
(RCC), which is the most common solid cancer of the adult kidney. RCC carcinogenesis is 
related to pVHL loss and Hypoxia Inducible Factor (HIF) activation, ultimately leading to the 
activation of several genes related to glycolysis. MicroRNAs (miRNAs) regulate gene 
expression at a post-transcriptional level and are also deregulated in several cancers, including 
RCC. 
SCOPE OF REVIEW: This review focuses in the miRNAs that direct target enzymes involved 
in glycolysis and that are deregulated in several cancers. It also reviews the possible application 
of miRNAs in the improvement of clinical patients’ management. 
MAJOR CONCLUSIONS: Several miRNAs that direct target enzymes involved in glycolysis 
are downregulated in cancer, strongly influencing the Warburg Effect. Due to this strong 
influence, FDG-PET can possibly benefit from measurement of these miRNAs. Restoring their 
levels can also bring an improvement to the current therapies.  
GENERAL SIGNIFICANCE: Despite being known for almost a hundred years, the Warburg 
Effect is not fully understood. MiRNAs are now known to be intrinsically connected with this 
effect and present an opportunity to understand it. They also open a new door to improve 
current diagnosis and prognosis tests as well as to complement current therapies. This is urgent 
for cancers like RCC, mostly due to the lack of an efficient screening test for early relapse 
detection and follow-up and the development of resistance to current therapies. 
 
 
Keywords: Renal cell Carcinoma, microRNAs, aerobic glycolysis, Warburg Effect  
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1. Introduction 
1.1. Cancer metabolism: the glucose pathway  
 
The reprogramming of energy metabolism was recently considered as one of the 
hallmarks of cancer and it has been object of interest and study during the past decade [1]. 
Recently, this reprogramming has been connected with microRNAs (miRNAs) since they are 
able to regulate gene expression at a post-transcriptional level in several human conditions, such 
as Renal Cell Carcinoma (RCC) [2,3]. In fact, one third of human genome is regulated by 
miRNAs [4]. Cancer cells have a higher rate of proliferation than normal cells. Because of that, 
they require an higher amount of energy, reductive power and intermediates as precursors for 
biosynthesis [5]. Cancer metabolism can be seen in two different scenarios: 1) When the supply 
of nutrients is optimal, the main goal of cancer cells is to acquire nutrients and to facilitate 
assimilation of carbon into macromolecules such as lipids, proteins and nucleic acids in order to 
support cell growth and proliferation; 2) When the resources are scarce, due to a harsh 
environment, cancer cells must be able to optimize the use of the nutrients and they have to 
modulate the microenvironment in order to obtain additional nutrients [6]. The main alterations 
in the metabolism reprogramming of cancer cells involve the metabolic pathways in glucose, 
amino acids, lipids as well as processes like autophagy, oxidative phosphorylation and ROS 
formation [7,8].  
Glucose is one of the major “fuels” of any cell and its consumption is altered in cancer 
due to metabolism reprogramming [9].  One of the first mechanisms of metabolism 
reprogramming to be discovered was the Warburg Effect and it is present in the majority of 
cancer cells. The Warburg Effect is also called aerobic glycolysis as it describes the preference 
of cancer cells to use glycolysis instead of oxidative phosphorylation, even in the presence of 
oxygen [10]. This occurs even though it appears not to be as efficient and despite the prevalence 
of mitochondria’s function [11]. Although Warburg Effect was first related over 90 years ago, 
its causes are still controversial. In addition to glycolysis, glucose metabolism which includes 
pentose phosphate pathways, serine synthesis pathways and tricarboxylic acid cycle, is 
somewhat altered when it comes to cancer cells in order to maximize the production of energy 
as well as the building of new blocks. Firstly, the consumption of glucose by cancer cells is 
higher than by normal ones, in part due to the higher expression of glucose transporters, such as 
the GLUT1 [12]. Besides that, several enzymes related to these pathways are known to be 
overexpressed in many types of cancer[13]. These enzymes include hexokinase (HK), aldolase 
(ALDOA), glyceraldeihydyde-3-phosphate dehydrogenase (GADPH), phosphoglycerate mutase 
1 (PGAM1) and Lactate dehydrogenase (LDH) in glycolysis as well as glucose-6-phosphate 
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dehydrogenase (G6PD) in pentose phosphate pathway or even serine synthesis pathway 
enzymes such as phosphoserine phosphatase (PSPH) [13]. Oncogenes and tumor suppressors 
can be responsible for this overexpression and transactivation. On the one hand, c-Myc,  
Hypoxia Inducible Factor-α (HIF-α) , K-RAS or AKT activate and promote the expression of 
these enzymes; on the other hand p53, genes from SIRT family and PTEN are responsible for 
inhibiting some of these enzymes or the oncogenes that promote their expression [6]. 
 
1.2. The Warburg Effect 
 
 During the 1920s, Otto Warburg was one of the first to report an alteration in cancer 
metabolism: the aerobic glycolysis occurrence [10]. He and his colleagues were measuring O2 
uptake and lactic acid production by cancer tissue, while calculating the amount of glucose 
consumed. Their data showed that cancer tissue consumed around ten times more glucose than 
normal tissue and produced more lactate as well. This was caused by an upregulated glycolysis. 
Also, even when there was a sufficient O2 supply, this kept happening. This singularity got 
known as Warburg Effect. Later, this process was demonstrated to be almost universal in cancer 
[11].  
 When there is oxygen, differentiated cells transform glucose in pyruvate, through 
glycolysis. After that, pyruvate gets into mitochondria and enters the tricarboxylic acid cycle, 
being transformed into carbon dioxide and NADH is produced. NADH then fuels oxidative 
phosphorylation producing a great amount of ATP, with minimal production of lactate. It is 
only when oxygen is lacking that cells use exclusively glycolysis to transform glucose and large 
amounts of lactate are produced [14]. As it was already reported, this is not what happens with 
the majority of cancer cells, which seem to prefer to obtain energy through aerobic glycolysis. 
However, comparing both situations it is easily understood that aerobic glycolysis is a highly 
inefficient method of obtaining energy. In fact, while complete oxidation of glucose to carbon 
dioxide generates 38 molecules of ATP, glycolysis only generates 2, which means that it would 
be necessary a 19 times higher uptake of glucose to keep the same metabolic level [15].   
 The Warburg Effect can be driven by the disruption of signaling pathways and by the 
deregulation of the expression of both metabolic enzymes and transport systems. HIF signaling 
pathway, when activated, increases the transcription of glucose transporters and of most 
glycolytic enzymes, such as LDH and PDK enzymes, restricting pyruvate entry into 
tricarboxylic acid cycle. PI3K pathway, in turn, integrates several molecules that are able to 
promote Warburg Effect, like AKT1 and mTOR and is itself an activator of HIF transcription 
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factors. Several glycolytic enzymes, like Hexokinase II (HK-2), PMK2 and PDKs are 
upregulated, promoting aerobic glycolysis. Furthermore, data shows that the activity and 
abundance of metabolites can also contribute to this effect, since transporters like GLUT 
(Glucose Transporter) and SGLT (an active transporter of glucose) are upregulated. In addition, 
data suggests that downregulation of MPC1 and MPC2, which are responsible for transporting 
pyruvate into the mitochondria, may help maintain the Warburg phenotype [16].    
 After more than 90 years the question that remains unanswered is: why do cancer cells 
undergo aerobic glycolysis, despite its apparent inefficiency? The first attempt to answer this 
question came from Warburg himself. He proposed that a dysfunction in mitochondria was the 
cause of this effect. This hypothesis was proven to be incorrect since roughly 66% of cells that 
kept oxidative phosphorylation capacity would metabolize through fermentation [11]. Later, in 
the 1970s, Efraim Racker proposed that the Warburg Effect originated from imbalances in 
intracellular pH due to defects in ATPase activity [17]. Despite several proposed causes of the 
Warburg Effect, they remain controversial and several hypotheses are still being discussed. 
Some believe that Warburg Effect comes as an advantage because it is a faster way for cancer 
cells to obtain ATP [18]. Others affirm that this effect supports better the high biosynthetic 
needs of these cells [19]. More recently, some scientists presented a theory saying this switch 
brings an acidification of the microenvironment, which is a great advantage to cancer cells, and 
others defend that this effect has direct signalling functions. [20] Even the theory that points 
Warburg Effect as the cause of carcinogenesis is still discussed nowadays [15]. Therefore, there 
is a continuous need of more studies and new experiments in order to support or revoke the 
theories described above.  
 
1.3.  Glycolysis in clear cell renal cell carcinoma 
 
Renal cell carcinoma (RCC) comprises a heterogeneous group of cancers that develop 
in the renal parenchyma. This type of cancer is derived from the nephron and it is the most 
common malignancy of the kidney, causing approximately 85% of all kidney tumors.  RCC has 
several subtypes with different genetic and molecular alterations, histological features and 
clinical phenotypes [21]. The three most common subtypes of RCC are the clear cell RCC 
(ccRCC), the papillary RCC (pRCC) and the chromophobe RCC (chRCC) [22]. ccRCC 
accounts for approximately 75% of all cases, and it is histologically characterized by a high 
tumor cell lipid content and a richly vascularized tumor stroma [23]. Surgery remains to be the 
only curative treatment for RCC since this tumor is resistant to both radio- and chemotherapy 
[24]. While RCC patients diagnosed with localized disease have a 5-year survival of 69%, the 5-
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year survival for patients with metastatic RCC (mRCC) is approximately 10 to 12% [24]. It is 
important to note that one third of patients are diagnosed with invasive disease and that 20 to 
40% of patients with organ confined disease will also develop metastasis [25].  The main reason 
for the poor prognosis in the mRCC is the acquired resistance to targeted therapies [26].  
Molecularly, one of the established signalling pathways involved in the 
pathophysiology of ccRCC is the pVHL/HIF pathway [27,28].  Although targeting HIF-α for 
proteolysis appears to be the dominant function of the von-Hippel Lindau tumor suppressor 
(pVHL), this tumor suppressor is also involved in the regulation of microtubule stability and 
cilia development and it is also required for embryonic development namely in the placental 
development and formation of several tissues [29]. Regarding the regulation of HIF-α, pVHL is 
the substrate recognition component of an E3 ubiquitin ligase and targets the hydroxylated HIF-
α subunits (HIF-1α and HIF-2α) for ubiquitination and proteasomal degradation under normoxic 
conditions [29]. Both HIF-1α and HIF-2α contain two transcriptional activation domains, the N-
terminal transactivation domain (NTAD) and the C-terminal transactivation domain (CTAD), 
enabling transcription once tethered to DNA [30]. Under normoxic conditions, the ability of 
HIF-α to activate transcription is prevented through HIF hydroxylation, which is catalyzed by 
prolyl hydroxylases (PHDs) near the NTAD and factor-inhibiting HIF (FIH) at the CTAD [31]. 
Subsequently, the pVHL protein binds to hydroxylated HIF-α and to elongin C, which recruits 
elongin-B, cullin-2 and ring-box 1 (RBX1) of an E3 ubiquitin ligase, targeting HIF-α for 
ubiquitination and degradation by the 26S proteasome [32]. During hypoxia, unhydroxylated 
HIF-α cannot bind to pVHL and therefore accumulates in the cell cytoplasm. Subsequently, 
HIF-α is translocated to the nucleus where it heterodimerizes with HIF-β. The HIF-α/HIF-β 
complex binds to hypoxia response elements (HREs) on nuclear DNA, recruits co-activators 
p300/CBP to the CTAD of HIF-α, and promotes the transcription of target genes [31,33]. Once 
activated, these genes are involved in several cellular pathways, namely the development of 
blood vessels (Vascular endothelial Growth Factor – VEGF; Vascular endothelial Growth 
Factor Receptor – VEGFR), cell proliferation (Transforming Growth Factor alpha – TGF-α), 
glucose metabolism (GLUT1 and GLUT4), pH regulation (Carbonic Anhydrase IX - CAIX) and 
cell migration (C-X-C motif chemokine receptor 4 - CXCR4) [27,34]. 
Patients with germline mutations in the VHL gene, located at chromosome 3p25, are 
affected by a rare autosomal dominant hereditary familial tumor syndrome, which is 
characterized by the increased risk to develop highly vascularized tumors in multiple organs. 
ccRCC is one of these highly vascularized tumors and it is the most aggressive one [35]. 
Sporadic ccRCC parallels the genetic mechanism of tumor initiation seen in VHL disease with a 
high frequency of cytogenetic losses at 3p25 as well as somatic VHL mutations which can be 
detected in 60 to 80% of patients with this type of cancer. About 60-80% of sporadic ccRCC 
cases display loss-of-function coding mutations in the VHL gene, chromosomal aberrations on 
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chromosome 3p25 that affect the VHL locus, or hypermethylation of the VHL promoter [34,35]. 
Regarding the other histological subtypes of RCC, VHL mutations are not observed in nonclear 
cell (papillary or chromophobe) histologies, however tumors described as histologically mixed 
variants including a component of clear cell may harbor these mutations [35].  
Since ccRCC is resistant to chemotherapy and radiotherapy, the understanding of the 
molecular mechanisms of the pVHL/HIF pathway in ccRCC, mainly related with VEGF and 
angiogenesis, led to the development of several target therapy options for patients with 
metastatic RCC (mRCC). However the drugs that modulate the pVHL/HIF/VEGF pathway are 
expensive, have significant side effects and an objective response rate was only observed in 
45% of patients, which may be due to the fact that these treatments don’t target directly the 
tumor cell, allowing the potential for disease progression despite treatment [33].  In fact, a 
subset of patients (~25%) do not seem to experience any clinical benefit from these targeted 
therapies, while in the majority of cases, patients respond to therapy initially but later develop a 
resistance and disease then progresses [26]. Usually, resistance to the targeted agents in ccRCC 
patients has been shown to develop after a median of 5-11 months of treatment [36]. These 
“failures” of targeted therapies show us the necessity of further investigation into the molecular 
pathways involved in ccRCC, mainly the mechanisms that lead to disease relapse and metastasis 
formation, in order to help the development of new effective targets and therapies, as well as the 
establishment of accurate biomarkers for disease follow-up and treatment response monitoring. 
The Warburg Effect is well documented in RCC. This effect can be driven by an 
interruption of the Krebs Cycle, germline inactivating mutations in genes that encode enzymes 
like Fumarate Hydratase or Succinate dehydrogenase, upregulation of HIF, increased levels of 
reactive oxygen species or activation of different pathways like NRF2/KEAP1 and 
PI3K/AKT/MTOR [37-39]. In ccRCC (both sporadic and hereditary), the most likely cause of 
the Warburg Effect is the upregulation of the HIF pathway. In most cases degradation of this 
molecule stops occurring due to VHL alteration. However, HIF-α can also be stabilized by 
mechanisms like RAS activation or accumulation of Krebs cycle substrates [40].  
In 2013, The Cancer Genome Atlas (TCGA) performed a comprehensive molecular 
characterization of ccRCC, using more than 400 ccRCC samples and concluded that patients 
that have tumors with higher stages and Fuhrman grades are associated with a metabolic shift 
consistent with a suppression of oxidative phosphorylation and a subsequent dependence upon 
glycolysis for energy [41]. The finding of the Warburg shift in ccRCC, opens the door for the 
development of new targeted therapies.  In a recent review, Schodel and co-workers, 
summarized the HIF target genes related to glycolysis in ccRCC, which would be possible 
therapeutic targets in targeted therapy involving the glycolysis pathway. The most relevant 
genes are the Glucose Transporter 1 (GLUT1), Lactate Dehydrogenase A (LDHA), Aldolase A 
(ALDOA), Hexokinase 2 (HK2), Phosphofructokinase (PFK) and Phosphoglycerate 1 (PGK1) 
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[34]. Additionally, sodium/glucose co-transporter 2 (SGLT2) can also be considered important 
for glucose metabolism in ccRCC, since it is expressed in the kidney tissue and is responsible 
for glucose reabsorption after glomerular filtration and may play a role in glucose metabolism 
[42].  
 
2. microRNAs as glycolysis regulators  
 
MiRNAs are a family of small non-coding RNAs (~19-25 nucleotides in length) that 
regulate gene expression by sequence-selective targeting of mRNAs, leading to their 
degradation or blockade at the post-transcriptional level. Target recognition occurs mainly by 
incomplete base pairing complementarity between the miRNA and the target mRNA resulting 
in mismatches that, in turn, lead to target gene silencing, which can occur via translational 
repression or mRNA degradation [43,44].  The outcome on proteomic level is dependent on the 
molecular abundance of the different target transcripts, indicating that the effect of a single 
miRNA can be cell type-dependent [45]. MiRNA expression is dynamic, since it is postulated 
that each miRNA regulates up to 100 different mRNAs and that more than 10.000 mRNAs 
appear to be directly regulated by miRNAs [46]. This variability makes miRNAs potent 
modulators of cellular behavior, since several miRNAs can target the same gene and one single 
miRNA can target multiple genes [47].  
Hence, miRNAs have been identified as key regulators in many biological processes 
including cell development, differentiation, apoptosis and proliferation, all of which are 
implicated in cancer development [48]. Many miRNAs have been identified to act as 
oncogenes, tumor suppressors or even modulators of cancer stem cells and metastasis formation 
[49]. On the one hand, oncomiRs are known to downregulate tumor suppressor genes, and they 
have been reported to be overexpressed in multiple miRNA-profiling studies [47,48]. On the 
other hand, tumor suppressor miRNAs are responsible for downregulating oncogenes, and are 
mostly underexpressed in cancer [49,50]. While it is clear that miRNAs play an important role in 
cancer biology, their multitude of targets and tissue specificity makes it difficult to understand 
the precise role they play in the disease process and the genes affected by their deregulation 
[51]. One example of this complexity is miR-34a, a well-studied microRNA, which has been 
shown to play a pivotal role in the progression of several types of cancer [52,53]. The miR-34a 
is a known mediator of p53-dependent tumor suppression, and low expression of this miRNA 
has been associated with worse prognosis in several cancers [54-57]. In RCC the role of this 
miRNA as a tumor suppressor is not very clear. Yu and colleagues demonstrated that miR-34a 
acts as a tumor suppressor in RCC by targeting CD44 and suppressing cell proliferation and 
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metastasis. Additionally, Du and co-workers showed that miR-34a was downregulated in 
hypoxic renal tubular epithelial cells, when compared with normal renal cells, and its 
downregulation promoted epithelial-mesenchymal-transition (EMT) [58,59]. However, several 
studies report that this miRNA is overexpressed in ccRCC and in the clear cell variant of pRCC, 
and its targets include GAS1, SFRP1, HFN4A and Axl [60-65]. These results highlight the fact 
that, despite being downregulated in other cancers, miR-34a seems to be upregulated in RCC, 
opening the debate to whether or not miR-34a is an important player in tumor suppression in 
RCC [53].  
One of the most important features of miRNAs is that they have different expression 
patterns in normal cells when compared with cancer cells, and even between cancer subtypes, 
which makes them excellent candidates for biomarkers [66]. Youssef and coworkers developed 
a classification system, using miRNA analysis and tissue samples, which can distinguish the 
different RCC subtypes using unique miRNAs signatures in a maximum of four steps. The 
system has a sensitivity of 97% in distinguishing normal RCC, 100% for clear cell RCC 
subtype, 97% for papillary RCC subtype and 100% accuracy in distinguish oncocytoma from 
chromophobe RCC subtype [66]. Additionally, several ccRCC oncogenes and tumor 
suppressors (EGFR, mTOR, VHL, HIF-1 α, PDGFβ) were detected as potential targets of 
miRNAs and several miRNAs have already been detected in biofluids of ccRCC patients and 
associated with disease prognosis [28,48,67,68]. However, the precise mechanisms by which 
these miRNAs participate in the regulation of renal carcinogenesis require further study. 
The study of the miRNAs involved in glycolysis regulation is highly important, mainly 
in cancers with the Warburg shift since that knowledge can be applied in the development of 
new-targeted therapies and biomarkers. In this review we summarize the current knowledge 
regarding miRNAs that target key enzymes of glycolysis that are deregulated in ccRCC and we 
also discuss the potential use of miRNAs as glycolysis biomarkers as well as therapeutic 
approaches for cancer treatment. 
 
2.1. Evidence Acquisition 
Systematic literature search in PubMed was conducted using the keywords or phrases, 
miRNAs, GLUT1 (Glucose Transporter Type 1), GLUT4 (Glucose Transporter Type 4), LDHA 
(Lactate Dehydrogenase A), ALDOA (Aldolase A), HK2 (Hexokinase 2), PFK 
(Phosphofructokinase), PGK1 (Phosphoglycerate 1) and SGLT2 (sodium/glucose co-
transporter 2). The articles were selected by relevance of their findings. All the references of 
the cited papers were reviewed and relevant publications in the field of metabolism involving 
the molecules studied were added.  
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 3. Evidence Synthesis 
HIF-1α is a transcription factor that acts at the level of mRNA synthesis to stimulate the 
production of glucose transporters and at least eight glycolytic enzymes when oxygen supply is 
limited or, in the case of RCC, when pVHL is absent and a pseudo-hypoxic environment is 
induced [69]. All the transporters and enzymes previously mentioned in section 2.1 were 
reported as up-regulated in RCC and are involved in important steps of glycolysis [34]. Their 
main functions, as well as the miRNAs that regulate them, and the models of disease in which 
they were studied are summarized in each section. In our search we did not find any information 
regarding PGK1 or SGLT2 regulation through miRNAs. In order to give the reader an 
integrative view of all the relations between the enzymes and the miRNAs, we summarized 
them in figure 1. 
 
3.1. Glucose Transporter Type 1 (GLUT1) 
The glucose transporter (GLUT) family is composed by 12 glucose transporters that 
vary in the tissue where they are expressed and with different physiological functions [69]. In 
order to engage the Warburg effect, cancer cells use much more glucose than a normal cell, 
which means that the ability for such cells to bring glucose into their cytoplasm needs to be 
increased. Glucose Transporter type 1 (GLUT1) is a glucose transporter whose function is basal 
glucose uptake. This transporter is ubiquitously expressed in all tissues and it is known to be 
deregulated in several cancers, especially those with high hypoxic rates [70-73]. In renal cell 
carcinoma, a recent study demonstrated that VHL deficient cell lines show synthetic lethality 
when GLUT1 was inhibited suggesting that this inhibition may be a potential therapy in cancers 
that depend only of aerobic glycolysis [74]. There are several studies reporting the miRNA 
regulation of GLUT1 in cancer models and they are listed in table 1. All the miRNAs listed 
target the 3’-UTR region of the GLUT1 mRNA and were reported to be deregulated in the 
cancer models where they were studied. 
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Table 1 – List of known miRNAs that regulate GLUT1 [75] [76] [77] [78] [79] [80] [81] [82]. 
miRNA Model Reference 
miR-144 Ovary cancer Fan et al 2015 
[75]
 
miR-144 Lung cancer Liu et al 2016 
[76]
 
miR-495 Glioma Nie et al 2015 
[77]
 
miR-132 Prostate cancer Qu et al 2016 
[78]
 
miR-186 Cancer Associated Fibroblasts Sun et al 2014 
[79]
 
miR-340 Oral Squamous Cell cancer Xu et al 2015 
[80]
 
miR-22 Breast cancer Chen et al 2014 
[81]
 
miR-1291 Renal Cell Carcinoma Yamasaki et al 2013 
[82]
 
 
 
 
 
3.2. Glucose Transporter Type 4 (GLUT4)  
Glucose uptake into myocytes and adipocytes is mediated by the glucose transporter 
type 4 (GLUT4). Between meals, some GLUT4 is present in the plasma membrane, but the 
majority is sequestered in the membranes of small intracellular vesicles inside the cells. Insulin 
released from the pancreas in response to high blood glucose triggers the movement of these 
intracelular vesicles to the plasma membrane, where they fuse, thus exposing GLUT4 molecules 
on the outer surface of the cell. Once GLUT4 molecules are activated, the rate of glucose uptake 
increases 15-fold or more [69]. GLUT4 has been described as deregulated in RCC. Data show 
that this transporter’s expression is downregulated in ccRCC but upregulated in chRCC, being 
an example on how different cancer subtypes may involve different altered pathways and 
molecules [83]. Despite being reported as deregulated in cancer, the miRNA regulation of this 
glucose transporter has been mainly studied in obesity and type 2 diabetes mellitus models, 
given its relation with insulin. The miRNAs that target GLUT4 mRNA are summarized in table 
2, as well as the models of disease in which they were studied.  
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Table 2 – List of known miRNAs that regulate GLUT4 [84] [85] [86] [87] [88] [89] [90] [91] [92]. 
miRNA Model Reference 
Let-7 Diabetes mellitus Li et al. 2016 
[84]
 
miR-106b 
miR-27a 
miR-30d 
Type 2 diabetes mellitus Zhou et al. 2016 
[85]
 
miR-29a Skelletal muscle  Zhou et al. 2016 
[86]
 
miR-29c Insulin-resistant heart Guedes et al. 2015 
[87]
 
miR-31 
miR-93 
miR-146a 
miR-199a 
Type 2 diabetes mellitus Yan et al. 2014 
[88]
 
miR-494 Chronic inflammation  Lee et al. 2013 
[89]
 
miR-93 Polycystic ovary syndrome Chen et al. 2013 
[90]
 
miR-223 Type 2 diabetes mellitus Lu et al. 2010 
[91]
 
miR-133 Cardiomyocytes Horie et al. 2009 
[92]
 
 
3.3. Hexokinase 2 (HK2)  
In the first step of glycolysis, glucose is activated for subsequent reactions by 
phosphorylation at C-6 to yield glucose 6-phosphate, with ATP as the phospohoryl donor. This 
reaction, which is irreversible under cellular conditions, is catalyzed by an enzyme called 
hexokinase (HK). There are four mammalian hexokinase isozymes (designed 1, 2, 3 and 4) that 
vary in subcellular locations, kinetics and physiological function. Hexokinase 2 (HK-2) is the 
principal regulated isoform in many cell types and is also increased in many cancers [69]. In 
ccRCC, HK-2 was shown to be upregulated while some components of the mitochondrial 
electron transport chain were downregulated, indicating an overall reprogramming of the 
energetic metabolism in this tumor type. This altered expression was also accompanied with 
deregulation of expression of genes involved in pH regulating machinery [93]. As we can see 
from table 3, the existing studies involving miRNA regulation of HK-2 were made mainly in 
cancer models and miR-143 seems to be an important player in this enzyme regulation.  
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Table 3 – List of known miRNAs that regulate HK2 [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107]. 
miRNA Model Reference 
miR-199a-5p Liver cancer Guo et al. 2015 
[94]
 
miR-143 Lung cancer Yao et al. 2014 
[95]
 
miR-143/miR-145 
cluster 
Renal Cell Carcinoma Yoshino et al. 2013 
[96]
 
miR-143 
Head and Neck Squamous 
Cell Carcinoma 
Peschiaroli et al. 2012 
[97]
 
miR-143 Prostate Cancer Zhou et al. 2015 
[98]
 
miR-143 Lung Cancer Fang et al. 2012 
[99]
 
miR-143 Breast Cancer Jiang et al. 2012
 [100]
 
miR-143 Colon Cancer Gregersen et al. 2012 
[101]
 
miR-143 Atherosclerosis 
Xu et al. 2016 
[102]
 
miR-125b Hepatocellular Carcinoma Jian et al. 2014 
[103]
 
miR-4458 Colon Cancer Qin et al. 2016 
[104]
 
miR-181a Mesenchymal Stem Cells Lee et al. 2015 
[105]
 
miR-181b Gastric Cancer Li et al. 2016 
[106]
 
miR-181c 
Cancer Associated 
Fibroblasts 
Lan et al. 2015 
[107]
 
 
 
3.4. Phosphofructokinase 1 (PFK-1)  
Phosphofructokinase 1 catalyzes the transfer of a phosphoryl group from ATP to 
fructose 6-phosphate to yield fructose 1,6-bisphosphate. The PFK-1 reaction is irreversible 
under cellular conditions and it is the first “commited” step in the glycolytic pathway since 
fructose 1,6-bisphosphate is only used for glycolysis [69]. Data showed that PFK protein’s level 
was significantly higher in RCC, in contrast with the mitochondrial DNA copy number which 
was significantly lower, showing a relation between an increase of glycolysis and the raise of 
invasiveness and drug resistance, in vitro [108]. Regarding miRNAs that regulate PFK-1 we 
only found one paper, and it was about PFKL (the liver type of PFK). The study, performed by 
Yang and co-workers, used as model lung cancer and concluded that miR-128 regulated PFKL 
(table 4). 
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Table 4 – List of known miRNAs that regulate PFKL [109]. 
miRNA Model Reference 
miR-128 Lung Cancer Yang J et al 2016 
[109]
 
 
 
3.5. Aldolase A (ALDOA)  
Aldolase is a key enzyme in the fourth step of glycolysis. It catalyzes the reversible 
conversion of fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone 
phosphate by aldol cleavage of the C3-C4 bond. As a result, it is an important enzyme in ATP 
biosynthesis for the cell. There are three aldolase isozymes (A, B and C) and they are 
differentially expressed during human development. Aldolase A (ALDOA) is ubiquitously 
expressed in most tissues, but it is predominantly expressed in the developing embryo and adult 
muscle tissue [69]. Despite its main function being the ATP biosynthetic process, this enzyme 
contributes to various cellular functions such as muscle maintenance, regulation of cell shape 
and mobility, striated muscle contraction and actin filament organization [110].  ALDOA has 
been found highly expressed in a variety of cancers, including lung, renal and hepatocellular 
carcinomas [110-112]. In ccRCC, ALDOA has been suggested as a candidate biomarker of late 
stages since it was overexpressed in stage IV but underexpressed in early stages relative to 
normal tissues [113].  Regarding ALDOA miRNA regulation, few studies exist, and they are 
mainly made in mouse models (table 5). 
Table 5 – List of known miRNAs that regulate ALDOA [114] [115] [116]. 
miRNA Model Reference 
miR-122 Liver Esau et al 2006 
[114]
 
miR-122 Human and rat liver cells Fabani et al 2008 
[115]
 
miR-16 MEG-01 cells Calin et al 2008 
[116]
 
 
3.6. Lactate Dehydrogenase A (LDHA)  
Lactate Dehydrogenase A (LDHA) belongs to the family of lactate dehydrogenases, and 
its function is to convert pyruvate, the final product of glycolysis, into lactate when oxygen is 
absent or in reduced supply. This enzyme is present in most somatic tissues, mainly in muscle, 
and an increase of its expression was reported in several human cancers [69]. Since the Warburg 
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effect increases the glycolysis rate in cells, it is expected an overproduction of pyruvate in 
cancer cells that needs to be converted in lactate, which will ultimately lead to an increase of 
LDHA. Moreover, in RCC cell lines, a study has shown a decrease in cell cycle and a 
promotion of apoptosis when LDHA is inhibited [117]. LDHA regulation by miRNAs has 
already been reported in some cancer models and miR-34a seems to have an important role 
(table 6)   
Table 6 – List of known miRNAs that regulate LDHA [118] [119] [120][121] [122] [123] [124] [125]. 
miRNA Model Reference 
miR-34a Cervical cancer Zhang et al 2016 
[118]
 
miR-34a Hepatocellular carcinoma Li et al 2016 
[119]
 
miR-34a Colon cancer Li et al 2015 
[120]
 
miR-34a Liver Wang et al 2015 
[121]
 
 miR-34a Colorectal cancer Kaller et al 2011 
[122]
 
miR-34a 
miR-34c 
miR-369-3p 
miR-374a 
miR-4524a/b 
Colorectal cancer Wang et al 2015 
[123]
 
miR-590-3p Type 2 diabetes mellitus Chen et al 2015 
[124]
 
miR-410 Gestational diabetes mellitus Mi et al 2015 
[125]
 
 
4. Glycolysis miRNAs’ and clinical patients’ management 
The detection of cancer and its characterization is one of the most important and 
continuously evolving part of cancer management. For many years the anatomic differences of 
tumors (in density, water content, shape and size) have been used to identify and characterize 
them through conventional imaging like plain radiography, ultrasound, computed tomography 
and magnetic resonance imaging [126].  
The ability to characterize tumor at a molecular level based on biochemical changes 
made 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) a revolution in 
imaging modalities [126]. In fact, since 2000, the number of FDG-PET scans done in United 
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States has increased about 9-fold and in 2011 it is estimated that 1,8 million have been 
performed with 94% of them for cancer. This technique is not only used in detection of cancer 
but also in staging as well as assessing therapeutic response and characterizing tumor biology 
[127-129]. PET uses labeled radiopharmaceuticals that, in the moment of their decaying, emit a 
positron. When a positron is emitted it encounters almost immediately an electron and is 
annihilated. However, this annihilation creates two gamma rays with opposing directions. These 
are the rays that are identified by PET exam, which with its software can convert the direction 
and wave size of the gamma ray in the position, direction and energy of its original positron. As 
so this exam can create three-dimensional images [126].  
Nowadays, PET has been conjugated with computed tomography (CT), being one of the 
main advantages of these hybrid technics the use of CT images for anatomic localization and 
attenuation correction. FDG is the most known radiopharmaceutical when it comes to PET 
technique. Its origin began with the work of Sokoloff, who was able to create a way of 
measuring regional cerebral glucose metabolism in animals [130]. In order to do that, he used 
14
C-deoxyglucose. This molecule is transported in parallel to glucose to the inside of the cell 
and it is phosphorylated by hexokinase too. However, 
14
C-deoxyglucose-6-phosphate, the 
product of that reaction lacks a hydroxyl group in Carbon 2 and it cannot be metabolized 
forward. As so it accumulates in cells. In the same way, FGD lacks a hydroxyl group in the 
same position and it is also trapped inside cells. When labeled with 
18
F, which is a positron-
emitting radioisotope, FDG can be analyzed with PET and the quantity of glucose in a certain 
area can be measured [131]. This quantification can be made over a period of time to measure 
the rate of uptake and trapping of a radiotracer or to estimate the density of a receptor of 
interest. This process is called dynamic imaging, however it is difficult to perform. As so, 
normally it is measured 60 minutes after injection with FDG and a standardized uptake value 
(SUV) is calculated. SUV represents the concentration of radioactivity in the area being 
analyzed, normalized to the injected dose and the body weight of the individual. SUV equals 1 
in an evenly distributed tracer [126].   
FDG’s use in detection of cancer is based on Warburg Effect. As described before, 
tumor cells show a higher rate of glycolysis, and of glucose uptake than normal cells. As so, 
cancer cells shall demonstrate higher amounts of FDG than normal cells and can be localized 
[132]. FDG has become truly popular in clinical use due to four main reasons. Firstly, this 
molecule is excreted by urine, which means it has a fast clearance. Secondly, hexokinase, which 
will convert FDG is ubiquitous and efficient, which means results that allow for cancer 
localization can be achieved by 60 minutes after FDG uptake. Thirdly, FDG uptake is very 
straightforward since there are few radiolabelled metabolites of it in the blood. Finally, FDG 
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can be produced at a central facility and then transported to a nearby imaging centre since 
18
F 
has a 110 minute half-life [126].  
FDG-PET is used for cancer detection, primarily in staging newly diagnosed or 
recurrent cancers. Moreover, researchers have recently showed that activation of several 
oncogenes leads to increased FDG uptake, which means that in many patients, the amount of 
FGD uptake can be a marker of tumor dedifferentiation [133]. However, false positives can 
happen and happen relatively commonly [132]. Infections and inflammations, muscular activity 
as well as metabolism of brown fat and changes in response to bone marrow-stimulating 
cytokines can increase FDG uptake, independently of malignancy [132]. FDG-PET can also be 
used to monitor tumor response,  since it can detect an early response to treatment. In fact it was 
shown that FDG-PET can demonstrate changes in tumor biology hours to days after the start of 
therapy [134]. However, FDG uptake can also increase in the beginning of some treatments due 
to greater inflammatory responses [135]. The use of FDG-PET for prognosis is still poorly 
understood. Since less differentiated and more rapidly proliferating tumors supposedly need 
more glucose to produce energy, it would be expected that FDG uptake reflected tumor grading. 
However, the correlation, even though positive, is not very strong [133]. Also, some benign 
tumors, such as giant cell tumors often show active FDG uptake which conflicts with this 
possible application [136]. 
Despite its wide use in cancer, the application of FDG PET/CT in renal cell carcinoma 
is limited, mostly because kidneys are the main way of physiological excretion of FDG, 
diminishing the contrast between lesions and normal tissue, thereby limiting the technique 
sensibility [132]. Therefore, international guidelines do not recommend FDG PET/CT as a 
diagnosis or staging tool [137]. However, it has shown efficiency in postoperative surveillance 
and restaging. Furthermore it can be a tool to differentiate benign from tumor lesions as well as 
to detect bone metastasis in RCC patients. It was also shown to be a useful prognostic and 
response to therapy marker. All this may affect therapeutic decisions and alter the outcomes of 
patients [132]. 
The measure of circulating miRNAs related to high glycolysis activity and tumor biology 
could be of great applicability to complement the FDG-PET exam, since they could help to 
eliminate the false positives and strengthen the relation between FDG uptake and tumor 
grading. 
MiRNAs have been shown to have great influence in expression of their target genes. The 
ones previously described in this article have great impact in regulation of glycolysis and 
glycolysis is one of the most deregulated metabolic processes in cancer. In the case of these 
miRNAs, they are generally downregulated in cancer, explaining the upregulation of glycolysis. 
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As so, we propose that the restore of the normal levels of these miRNAs could replace 
glycolysis’ normal levels and could bring benefits to currently cancer therapies. 
One possibility to restore the original levels of these miRNAs is the delivery of such 
molecules through exosomes to cancer cells. Delivery of miRNAs by exosomes brings the 
advantage of them not being recognized as strangers by immune systems, due to their biological 
origin [138]( (Figure 2). This delivery is achieved through the design of exosomes by 
nanotecnological methods or by altering exosomes so they show certain characteristics. 
Therefore the choice of the exosome’s donor cell is one of the first decisions in the development 
of this delivery method. This cell shall produce exosomes that are able to circulate in the system 
enough time to deliver the miRNA and that don’t have any immune stimuli in order to prevent 
inflammatory responses. The selected miRNA can be inserted into the exosome by several 
methods, such as electroporation, incubation or transfection. At its surface exosomes must have 
specific antibodies or ligands that are highly expressed in the target cell so they can be absorbed 
by it. The administration of these exosomes can be made through different ways depending of 
the location of the cancer (intravenous, oral, intraperitoneal, intra-tumoral, intranasal or 
subcutaneous) [139]. 
 
5. Conclusion 
In this review we highlighted an altered pathway in clear cell renal cancer that may be a 
potential target to improve diagnosis and prognosis exams as well as to develop new 
therapeutically strategies. The reality of the non-existence of an efficient screening test for early 
relapse detection and follow-up in RCC has been haunting the field of Oncology for the past 
years once RCC is the most lethal urologic neoplasia. Even though scientists have been making 
an effort to understand why cancer cells undergo the metabolism switch to aerobic glycolysis 
for almost a hundred years, this is not yet understood. However, the Warburg effect is present in 
the majority of cancer cells. MiRNAs are known to be deregulated in cancer and for the past 
few years several studies have implicated specific miRNAs that direct target enzymes involved 
in glycolysis. Presently, there is still need for more studies to demonstrate and clarify the key 
miRNAs profiles involved in RCC aerobic glycolysis and their potential to be used as molecular 
biomarkers. Moreover, more possible targets should be studied for each one of the miRNAs 
since there is the possibility the same miRNA may target several of those enzymes. 
Additionally, once stablished as biomarkers they could be detected by non-invasive techniques 
allowing a more accurate disease monitorization and an early detection of relapse. We propose 
that the associations in this study may bring a new possibility of diagnosis and treatment in 
cancers with high glycolytic rates, such as ccRCC. Measuring the expression levels of 
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glycolysis-related miRNAs can help improve FDG-PET exam by eliminating false positives and 
strengthening the relation between FDG uptake and tumor grading. Since these miRNAs seem 
to be downregulated in cancer, one new therapeutic approach could be restoring their levels, 
which would block glycolysis and cut the source of energy of cancer cells. Due to their 
specificity and stability in circulation, we propose that the delivery of these miRNAs can be 
done using exosomes.  
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Figure 1- Model of miRNAs involved in the aerobic glycolysis in ccRCC pathophysiology. The 
loss of pVHL leads to the accumulation of HIF-α in the nucleus and consequent binding to 
transcription factors such as GLUT1. This causes an up-regulation of glucose metabolism in 
which several miRNAs are involved. 
 
Figure 2– Model of an exosome-based delivery system design. After loading the exosomes with 
the desired cargo (such as miRNAs), they can be administrated to the patient through several 
ways, which include oral and intranasal, that are minimally invasive and non-painful.  
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Fig. 2 
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Highlights 
 
 The switch of cancer cells metabolism to aerobic glycolysis is not yet 
understood 
 The Warburg effect is associated with a renal cell carcinoma worse prognosis  
 microRNAs are responsible for regulating key mRNAs associated with  
glycolysis  
 microRNAS’ may be used for the improvement of clinical patients’ management 
